Podcasts about Coa

Depuis le PLF 2025, on lit partout que le LMNP est mort. Stefano Demari, lui, vient d'enregistrer les meilleurs mois de l'histoire de JD2M : 3 000 nouveaux inscrits en mai 2026, soit le double de l'année précédente. Croissance de 40% sur l'année. Stefano Demari est président et co-CEO de JD2M - Je Déclare Mon Meublé, la plateforme qui traite les déclarations fiscales LMNP de 80 000 clients en France, soit près de 100 000 lots. Il a aussi porté la voix des bailleurs meublés directement au Parlement lors des débats sur le PLF 2025. Dans ce troisième et dernier volet de notre hors-série Immobilier, nous démontrons les idées reçues sur la mort du LMNP.Au programme : Ce que le PLF 2025 a vraiment changé pour les investisseurs, et ce qu'il n'a pas changé Pourquoi la réintégration des amortissements dans la plus-value est bien moins catastrophique qu'annoncé Pourquoi autant d'investisseurs laissent de l'argent sur la table en déclarant mal, et pourquoi la première année est la plus critique Meublé, location nue, bailleur privé (loi Jeanbrun) : qui gagne vraiment en 2026 ? Comment Stefano voit le marché évoluer dans les deux prochaines années  Code promo JD2M : JUSTFOCUS, 10% de réduction sur jd2m.fr, valable 1 an pour les nouveaux clients.  Pour aller plus loin : Hors-Série Immobilier #1 - Immobilier 2026 : décrypter le cycle pour bien investir, avec Jean-Baptiste Pracca https://sapians.com/blog/podcast-immobilier-jean-baptiste-pracca-mata-capital Hors-Série Immobilier #2 - Crédit immobilier et entrepreneurs : comment présenter votre dossier à la banque, avec Jean-Baptiste Monié https://sapians.com/blog/podcast-immobilier-jean-baptiste-monie-carte-financement Investir dans l'immobilier locatif ou dans un fonds immobilier ? https://sapians.com/blog/investir-dans-immobilier-locatif-ou-dans-fonds-immobilier-----------------------Attention : Ceci est une communication publicitaire. Les performances passées ne préjugent pas des performances futures et investir comporte des risques de perte partielle ou totale en capital. Ce contenu est informatif et ne constitue pas un conseil en investissement. Toute décision doit être adaptée à votre situation. Si vous souhaitez bénéficier de conseils personnalisés, veuillez créer votre compte ou prendre rendez-vous avec un conseiller Sapians. SAPIANS - RCS n°919 330 969 - ORIAS n°23003561 en qualité de CIF et COA. Activité de démarchage bancaire et financier.

This source explains that unlike other nutrients, amino acids contain nitrogen, which poses a unique challenge during metabolic breakdown. Because the body cannot store surplus amino acids as it does with fats or sugars, it must either use them for protein synthesis or dismantle them for energy. When these molecules are broken down, the nitrogen is converted into ammonia, a toxic byproduct that requires the urea cycle for safe elimination. The remaining carbon skeletons are repurposed for energy production. Ultimately, the carbon skeletons are converted to either glucose or acetyl CoA. The latter two molecules are oxidized to CO2 to produce energy.

On sort de la correction immobilière la plus violente depuis 2009. Les volumes d'investissement en Europe ont chuté à 145 milliards en 2023, avant de remonter à 215 milliards en 2025. Les institutionnels reviennent progressivement. Et pourtant, beaucoup d'investisseurs privés hésitent encore : est-ce le bon moment ? Que faire de son capital immobilier dans ce contexte ? Jean-Baptiste Pracca a cofondé Mata Capital il y a dix ans. Il analyse les cycles depuis les données brutes jusqu'aux comportements des acheteurs, et il voit des centaines de dossiers chaque année. Son regard sur le marché est tranchant, et ses convictions, parfois contre-intuitives. Dans cet épisode, il décrypte les mécanismes du cycle actuel, explique pourquoi la gestion passive ne fonctionne plus dans ce nouveau paradigme de taux, et dresse une cartographie honnête des classes d'actifs : là où les opportunités sont réelles, là où les destructions de valeur ne sont pas terminées. Il revient aussi sur l'erreur stratégique des SCPI, sur la thèse opco-propco en hôtellerie et résidentiel géré, et donne trois convictions fortes sur l'immobilier européen pour les cinq prochaines années. Un épisode dense, construit sur des données concrètes, pour ceux qui veulent comprendre le marché avant d'agir. Des ressources pour approfondir : Investir en SCPI : avis, contexte de marché, points de vigilance https://sapians.com/blog/investir-scpi-avisQue savoir pour investir en private equity immobilier ? https://sapians.com/blog/investir-private-equity-immobilierInvestir dans des fonds immobiliers value-added https://sapians.com/blog/classement-meilleur-fonds-immobilier-value-added-2025Comment investir dans l'immobilier en période d'inflation ? https://sapians.com/blog/investir-immobilier-periode-inflation -----------------------Attention : Ceci est une communication publicitaire. Les performances passées ne préjugent pas des performances futures et investir comporte des risques de perte partielle ou totale en capital. Ce contenu est informatif et ne constitue pas un conseil en investissement. Toute décision doit être adaptée à votre situation. Si vous souhaitez bénéficier de conseils personnalisés, veuillez créer votre compte ou prendre rendez-vous avec un conseiller Sapians. SAPIANS - RCS n°919 330 969 - ORIAS n°23003561 en qualité de CIF et COA. Activité de démarchage bancaire et financier.

Tomorrow's podcast is a little different. We're doing a two-part episode. First, we're diving into some of the biggest health and peptide mistakes I'm seeing right now...mistakes that can waste money, delay healing, and in some cases actually make health challenges worse. Then we're going to celebrate one of our amazing CHI members, Susan, who chose a very different path. Instead of guessing. Instead of chasing symptoms. Instead of jumping from supplement to supplement, practitioner to practitioner, or peptide to peptide. She decided to understand what was actually standing in the way of her health. Susan completed advanced testing that revealed she was carrying and actively releasing pesticides, plastics, mold toxins, and other environmental toxicants. She learned where to focus. She followed a roadmap. And she took action. Before I tell you more about Susan's story, here's what we'll cover in today's episode:

ABOUT THE EPISODEListen in as David Schrock and Stephen Wellum interview Knox Brown on his COA essays, "Divine Energies: Eastern Orthodoxy's Strangest and Most and Most Important Doctrine" and "All Protestants God to Hell": Eastern Orthodoxy's Official Rejection of the Gospel at the Synod of JerusalemSponsorThis month's sponsor is Grimke Seminary. Pastors are called to care for the church of God that God called them to. So why do seminaries require men to leave their church to pursue theological studies? At Grimké Seminary, you can get Christ-centered, theological training in the Reformed, Protestant tradition, without leaving your local church. They offer a range of pastoral studies for students of all backgrounds to serve your growth in ministry, from a Bachelor's to a Doctor of Ministry.To apply, go to grimkeseminary.org and use the code “christoverall” to have your application fee waived.Timestamps00:37 – Intro04:43 – Knox's Exposure to Eastern Orthodoxy07:10 – Hans Boersma10:46 – Knox's Article on the Doctrine of God13:10 – Essence and Energies17:14 – Explaining How the Energies are Existing Enhypostatically19:56 – What Does Being Canonized Mean?21:40 – How Does This All Relate to the Economic Trinity?24:12 – In EO, How Do We Share in the Energies?29:27 – Sponsor: Grimké Seminary36:37 – The Council of Jerusalem38:57 – Is Cyril Lukaris Still a Saint?40:10 – How Prominent is the Council of Jerusalem?43:45 – Different Weights and Measures on Schism53:40 – Reading the Councils to Know What You Gain and What You Lose in EO57:35 – OutroResources to Click“Divine Energies: Eastern Orthodoxy's Strangest and Most Important Doctrine” – Knox Brown“All Protestants Go to Hell: Eastern Orthodoxy's Official Rejection of the Gospel at the Synod of Jerusalem” – Knox Brown“The Acts and Decrees of the Synod of Jerusalem, Sometimes Called the Council of Bethlehem, Holden under Dositheus, Patriarch of Jerusalem in 1672”“The Delayed Synodical Receptions of the Councils of Jasy (1642) and Jerusalem (1672)” – Craig Truglia“Georgian Orthodox Church” – Wikipedia“When Did Today's Autocephalous Churches Come Into Being?” – Orthodox History“Eastern Orthodox and Oriental Orthodox: What's the Difference?” – TheoriaTheme of the Month: Go West, Young Men: Evaluating the Drift toward Eastern OrthodoxyGive to Support the Work

En tant qu'entrepreneur ou dirigeant, avez-vous déjà eu l'impression que votre banquier ne savait pas vraiment quoi faire de votre dossier immobilier ? Revenus atypiques, sociétés imbriquées, projet un peu hors-norme : vous faites partie de la catégorie des dossiers que les banques traditionnelles ne savent pas toujours bien accompagner.Jean-Baptiste Monié, cofondateur de Carte Financement, a fait de cette catégorie son métier depuis 2009.  Dans un contexte de taux incertains et de marché immobilier sous tension, il partage sa lecture de terrain et les leviers concrets que la plupart des dirigeants n'utilisent pas, faute de les connaître. A la fin de cet épisode, vous saurez : Comment se forment les taux immobiliers et quels indicateurs suivre pour anticiper leur évolution ? Pourquoi la règle des 35% d'endettement ne s'applique pas toujours à un dirigeant Faut-il acheter ses bureaux en ce moment ? A quelles conditions l'équation tient-elle ? Crédit Lombard, crédit hypothécaire : quand ces outils ont-ils du sens dans une stratégie patrimoniale ? Comment structurer un financement immobilier quand votre situation sort des cases bancaires ? -----------------------Quelques ressources pour aller plus loin : Réaliser un audit patrimonial : pourquoi ? Comment ? https://sapians.com/blog/audit-patrimonial-----------------------Attention : Ceci est une communication publicitaire. Les performances passées ne préjugent pas des performances futures et investir comporte des risques de perte partielle ou totale en capital. Ce contenu est informatif et ne constitue pas un conseil en investissement. Toute décision doit être adaptée à votre situation. Si vous souhaitez bénéficier de conseils personnalisés, veuillez créer votre compte ou prendre rendez-vous avec un conseiller Sapians. SAPIANS - RCS n°919 330 969 - ORIAS n°23003561 en qualité de CIF et COA. Activité de démarchage bancaire et financier.

226: On this episode, we are back from a week away because of setup and working the 2026 Northern Illinois Section Championship! Springfield offers a stripper version of the Echelon and COA on the Prodigy LSI looks to have a new 2011 grip in the horizon with removable grip panels Jaki shoots her first major in a long time Tony has a HORRENDOUS start to his match! Check Out Our Partners & Affiliates For The Best Deals On Gear:

226: On this episode, we are back from a week away because of setup and working the 2026 Northern Illinois Section Championship!Springfield offers a stripper version of the Echelon and COA on the ProdigyLSI looks to have a new 2011 grip in the horizon with removable grip panelsJaki shoots her first major in a long timeTony has a HORRENDOUS start to his match! Check Out Our Partners & Affiliates For The Best Deals On Gear:

"Mother Nature provides us with all the food and medicine that we need. Food is medicine — and it is the number one thing you can do for any person or animal to help them stay healthy and help their immune system operate." This episode is sponsored-in-part by Maddie's Fund, OcuTrap, and The Kitten Conference. What if the best medicine for your community cats isn't found in a bottle — but in a bowl? In this episode, host Stacy LeBaron sits down with Angela Ardolino, a certified cannabis and fungi clinician with over 20 years of expertise in holistic pet wellness and founder of MycoDog, MycoCat, and CBD Dog Health. Angela's path to holistic animal care began with her own recovery from rheumatoid arthritis using plants, mushrooms, and diet — which led her to discover that every animal shares an endocannabinoid system, the body's master regulatory system. With no quality animal products on the market, she spent two years formulating and testing full-spectrum hemp extract and medicinal mushroom tinctures at her rescue farm before bringing them to the public. Stacy and Angela dig into the real cost of kibble — not just financially, but biologically — and make the case for real food, even in small increments, for both owned cats and colony cats. Angela also offers practical guidance on supporting senior and geriatric cats with full-spectrum hemp extract, how to spot trustworthy supplements (look for a COA), and why the endocannabinoid system is the key to keeping cats healthy from the inside out. Press Play Now For: Why kibble is the wrong foundation for feline health — and practical, budget-friendly alternatives for pet owners and colony caregivers alike How the endocannabinoid system works in all animals and why supporting it is key to preventing disease How to administer full-spectrum hemp extract to cats you can touch — and cats you can't Why 85% of supplements on the market (for pets and humans alike) aren't worth buying, and how to identify the ones that are When a cat becomes a "senior" vs. a "geriatric" — and why that distinction matters for their care The feline grimace scale, telehealth options, and emerging tools that help caregivers monitor cats without a vet visit A vision for mobile veterinary care that extends to colony sites, not just indoor pets Resources & Links Angela Ardolino's Website CBD Dog Health MycoDog Your Natural Dog Podcast Follow Angela on Instagram Follow Angela on Facebook Follow Your Natural Dog on Instagram

C'est trop facile de raconter un deal en ne regardant que d'un côté. Alors aujourd'hui, nous avons voulu réunir les deux : le fonds et l'entrepreneur qu'il accompagne, pour qu'ils racontent leurs versions de la même histoire, et partagent leurs points de vue, parfois complètement différents. Pour ce format inédit, Aurore Perrin reçoit Laurent Foiry, co-fondateur de Spring Invest, fonds spécialisé dans la transformation du commerce, et Martin, fondateur d'Acolyt, logisticien 3PL premium pour marques de mode et cosmétique.  Ensemble, ils reviennent sur cinq ans d'une relation qui a commencé par une rencontre. Au départ, rien ne laissait présager qu'elle mènerait à une levée de fonds.Parmi les sujets abordés dans cet interview croisée : Qu'est-ce qu'un fonds peut apporter qu'aucun banquier ne peut vous donner ? Jusqu'où un entrepreneur doit-il être transparent avec son investisseur ? Pourquoi faire petit peut être la stratégie la plus ambitieuse qui soit ?  Quand décide-t-on que c'est le bon moment de se séparer ?  Bonne écoute !  -----------------------Attention : Les performances passées ne préjugent pas des performances futures et investir comporte des risques de perte partielle ou totale en capital. Ce contenu est informatif et ne constitue pas un conseil en investissement. Toute décision doit être adaptée à votre situation. Si vous souhaitez bénéficier de conseils personnalisés, veuillez créer votre compte ou prendre rendez-vous avec un conseiller Sapians.SAPIANS - RCS n°919 330 969 - ORIAS n°23003561 en qualité de CIF et COA. Activité de démarchage bancaire et financier.

Le private equity evergreen fait rêver : la performance du non-côté, avec la liquidité en prime ! Mais n'est-ce pas un peu trop beau pour être vrai ?Étienne de Saint-Germain, responsable de l'offre et des services chez Sapians, analyse des centaines de fonds chaque année. Il nous retrouve aujourd'hui pour démystifier les fonds evergreen : un véhicule en pleine explosion mais dont les promesses alléchantes méritent d'être passées au crible.Dans cet épisode, découvrez :Ce qui distingue un fonds evergreen d'un fonds classique.Comment la liquidité est organisée dans des actifs illiquides et où elle trouve ses limites.Pourquoi ces fonds performent structurellement moins.Les critères spécifiques à analyser avant d'y investir.-----------------------Attention : Les performances passées ne préjugent pas des performances futures et investir comporte des risques de perte partielle ou totale en capital. Ce contenu est informatif et ne constitue pas un conseil en investissement. Toute décision doit être adaptée à votre situation. Si vous souhaitez bénéficier de conseils personnalisés, veuillez créer votre compte ou prendre rendez-vous avec un conseiller Sapians.SAPIANS - RCS n°919 330 969 - ORIAS n°23003561 en qualité de CIF et COA. Activité de démarchage bancaire et financier.

In Loosdrecht, IJsselstein en Den Bosch liep het verzet tegen nieuwe asielzoekerscentra de afgelopen weken uit de hand: de politie werd bekogeld, een snelweg bezet en ruiten van gemeentehuizen sneuvelden. Tegelijkertijd moet het COA nu al onmenselijke keuzes maken, ziet redacteur Martin Kuiper. Komen we hier nog uit?Gast: Martin KuiperPresentatie: Bram EndedijkRedactie: Elze van Driel & Yara van HeugtenMontage: Andy ClarkEindredactie: Anna KorterinkCoördinatie: Ilse EshuisProductie: Rhea Stroink Heb je vragen, suggesties of ideeën over onze journalistiek? Mail dan naar onze redactie via podcast@nrc.nl.Zie het privacybeleid op https://art19.com/privacy en de privacyverklaring van Californië op https://art19.com/privacy#do-not-sell-my-info.

De asielcrisis loopt vast, de onvrede in de samenleving groeit en de AIVD mengt zich nadrukkelijk in het publieke debat. Worden de spelregels van onze democratie herschreven?In deze uitzending van DNW Politiek gaan Ad Verbrugge en Jelle van Baardenwijk in gesprek met Jasper van Dijk over de explosieve situatie rondom de asielopvang. De beelden van de burgemeester in Loosdrecht en de noodkreet van het COA laten zien dat de rek er bij zowel het bestuur als de bevolking volledig uit is. Is er sprake van onmacht, of kijken we naar een bewuste beleidsagenda die aanstuurt op een paradigmawisseling?Daarnaast duiken we in het recente jaarverslag van de AIVD. De inlichtingendienst waarschuwt voor 'anti-institutioneel extremisme' en 'narratieven' in alternatieve media. Maar wie bepaalt wat desinformatie is en wat een legitieme afwijkende mening? Ad en Jelle analyseren de gevaarlijke grens tussen veiligheid en het monddood maken van overheidskritiek.-------------Steun DNWMaak het geluid van de Nieuwe Wereld mogelijk. Zonder uw steun geen DNW! Word lid of doneer:

Ce ne sont pas seulement les marchés qui détruisent la performance des investisseurs particuliers. Ce sont aussi leurs décisions, prises sous l'influence de biais comportementaux, dont ils n'ont pas conscience.  Aversion au risque, effet de disposition, biais domestique : ces mécanismes sont documentés, mesurables... Et peuvent vous coûter 4 à 7% de performance boursière annualisée. Dans cet épisode, Nour Bendimered, Directeur des Investissements Marchés financiers chez Ivesta vous aide à prendre conscience de ces pièges et adopter une méthode pour en limiter l'impact sur votre patrimoine. Découvrez : Pourquoi nos décisions d'investissement sont bien moins rationnelles qu'on ne le croit. Les biais cognitifs qui affectent la majorité des investisseurs particuliers. L'impact réel de ces biais en termes de performance annualisée. Les méthodes concrètes pour limiter l'impact des émotions sur vos décisions d'investissement. -----------------------Attention : Les performances passées ne préjugent pas des performances futures et investir comporte des risques de perte partielle ou totale en capital. Ce contenu est informatif et ne constitue pas un conseil en investissement. Toute décision doit être adaptée à votre situation. Si vous souhaitez bénéficier de conseils personnalisés, veuillez créer votre compte ou prendre rendez-vous avec un conseiller Sapians.SAPIANS - RCS n°919 330 969 - ORIAS n°23003561 en qualité de CIF et COA. Activité de démarchage bancaire et financier.

This podcast explains how the body maintains stable blood glucose levels while following a carbohydrate-free ketogenic diet. Since the metabolism of fatty acids produces acetyl-CoA, which cannot be converted into glucose, the body must rely on other mechanisms to fuel the brain and red blood cells. Hormones like glucagon and epinephrine trigger the liver to activate gluconeogenesis, a process that synthesizes new sugar. Because fats are ineligible for this conversion, the liver utilizes the carbon skeletons of amino acids derived from dietary protein to create glucose. Ultimately, the high protein content of a keto diet is essential for replenishing glycogen stores and ensuring the body has a consistent energy supply.

PEA, PER, assurance-vie, épargne salariale, compte-titres, contrat de capitalisation… Vous connaissez leurs noms. Mais savez-vous vraiment laquelle correspond le mieux à votre situation ? Comment bénéficier pleinement de leurs atouts ? Et ce que ça vous coûte de mal les utiliser ?Dans cet épisode, Étienne de Saint Germain, family-officer et responsable de l'offre et des services chez Sapians, passe en revue des enveloppes incontournables et leurs spécificités (fiscalité, avantages, inconvénients, conditions...).Découvrez :Les PEA et PEA-PME, deux enveloppes complémentaires dont les avantages fiscaux vont bien au-delà de ce qu'on imagine.Ce que personne ne vous dit sur l'assurance-vie française : est-ce vraiment l'enveloppe fiscale ultime ?Les utilisations les plus judicieuses du plan d'épargne retraite (PER). Attention, il n'est pas fait pour tous. Il peut être un puissant levier fiscal si (et seulement si) votre situation s'y prête vraimentDans quels cas vous méfier de l'épargne salariale proposée par votre entreprise (sa fiscalité attractive peut masquer des performances décevantes...)Pourquoi le contrat de capitalisation et le compte-titres ordinaire méritent toute votre attention. Ces enveloppes sont sous-estimées et pourtant redoutables !Bonne écoute ! ATTENTION : suite à la loi de finances 2026, les prélèvements sociaux sont désormais de 18,6 % (au lieu de 17,2 % comme mentionné dans l'épisode) et la flat tax (prélèvement forfaitaire unique) s'élève à 31,4 % (anciennement 30 %).Des ressources pour approfondir : Qu'est-ce que le PER ? Son fonctionnement et ses avantages https://sapians.com/blog/plan-epargne-retraite-comment-ca-marcheComment fonctionne l'assurance-vie française ? https://sapians.com/blog/fonctionnement-assurance-vie-francaise Optimiser sa transmission de patrimoine avec le PER https://sapians.com/blog/patrimoine-transmission-per-plan-epargne-retraiteTout ce qu'il faut savoir sur les transferts de PEA, PER, PERCO https://sapians.com/blog/transfert-pea-perTout savoir sur le compte-titres ordinaire https://sapians.com/blog/compte-titresDans quelle enveloppe loger ses investissements en private equity ? https://sapians.com/blog/enveloppe-private-equity -----------------------Attention : Les performances passées ne préjugent pas des performances futures et investir comporte des risques de perte partielle ou totale en capital. Ce contenu est informatif et ne constitue pas un conseil en investissement. Toute décision doit être adaptée à votre situation. Si vous souhaitez bénéficier de conseils personnalisés, veuillez créer votre compte ou prendre rendez-vous avec un conseiller Sapians.SAPIANS - RCS n°919 330 969 - ORIAS n°23003561 en qualité de CIF et COA. Activité de démarchage bancaire et financier.

Vandaag is Robert Paul Schwippert te gast bij Jelle van Baardenwijk. Robert Paul maakte een opmerkelijke carrièreswitch: van organisatieadviseur in de internationale olie-industrie naar casemanager bij het Centraal Orgaan opvang asielzoekers (COA). In zijn boek 'In de wachtkamer van de toekomst' deelt hij zijn ervaringen van de werkvloer in het azc van Almere.In dit gesprek duiken we in de weerbarstige praktijk van de asielopvang. Robert Paul legt uit hoe het systeem momenteel vastloopt: van statushouders die jarenlang tussen "dunne wandjes" wachten op een woning, tot de frustrerende bureaucreatie rondom werkvergunningen en taalonderwijs. Waarom verspillen we zoveel talent? En hoe kunnen we de dialoog tussen het azc en de samenleving herstellen?In dit gesprek bespreken we de cultuurshock van een consultant binnen het COA en analyseren we waarom de inburgeringswet in de praktijk vaak te laat start. Ook staan we stil bij het contrast tussen hoopvolle nieuwkomers en de neerslachtigheid die ontstaat door het lange wachten. Daarnaast komt de impact van de Spreidingswet aan bod.--------Koop nu je kaartjes voor de Theater Tour! ⭐7 mei: Op Hodenpijl, Schipluiden met Kees de Kort: https://ophodenpijl.nl/evenement/nieuwe-wereld-kees-de-kort/?occurrence=2026-05-0719 mei: Grote Kerk Alkmaar met Maurice de Hond: https://grotekerkalkmaar.nl/tickets/seizoen-25-26/de-nieuwe-wereld-ondergang-van-het-avondland/?showId=3878151937-177159177816 juni: De Maagd, Bergen op Zoom: Willem Middelkoop: https://www.demaagd.nl/agenda/ondergang-van-het-avondland-de-nieuwe-wereld-4xn6Bestel het boek van Robert Paul: https://vangennep-boeken.nl/in-de-wachtkamer-van-de-toekomst-robert-paul-schwippert?srsltid=AfmBOoowhFK0w9eWWjYE9cMilGmddKBHFwguclVZE8g8VYIPIQkhnE51

Michael Jewett is a pioneer of cell-free biotechnology. Instead of using living microbes as factories, he uses their internal molecular machinery to make valuable proteins, medicines, diagnostics, and other chemicals. Jewett recently used the technique for vaccine production in an approach that could produce up to 150,000 doses from one liter. He believes cell-free biotech could democratize the production of essential medicines, improve water safety, and help convert atmospheric carbon into useful products, among other promising possibilities. “It's just-add-water biotechnology,” Jewett tells host Russ Altman on this episode of Stanford Engineering's The Future of Everything podcast. Have a question for Russ? Send it our way in writing or via voice memo, and it might be featured on an upcoming episode. Please introduce yourself, let us know where you're listening from, and share your question. You can send questions to thefutureofeverything@stanford.edu. Episode Reference Links: Stanford Profile: Michael Christopher Jewett Connect With Us: Episode Transcripts >>> The Future of Everything Website Connect with Russ >>> Threads / Bluesky / Mastodon Connect with School of Engineering >>> Twitter/X / Instagram / LinkedIn / Facebook Chapters: (00:00:00) Introduction Russ Altman introduces Mike Jewett, a professor of bioengineering and chemical engineering at Stanford University. (00:03:23) What Is Cell-Free Biotechnology? Using the internal machinery of cells without the cells themselves. (00:04:20) Removing “Evolutionary Baggage” Why cells' natural priorities can conflict with engineering goals. (00:07:41) Advantages of Cell-Free Systems From large-scale production to decentralized, on-demand manufacturing. (00:11:40) Making Proteins Outside Cells How DNA instructions are used to produce functional proteins. (00:13:49) Biosensors for Water Safety Detecting contaminants like lead using engineered proteins. (00:17:05) Engineering Better Sensors Improving sensitivity and selectivity through protein design. (00:20:33) AI in Bioengineering How data and models accelerate discovery and design. (00:23:22) Sustainability & Carbon Capture Turning atmospheric carbon into useful chemicals. (00:26:18) Building New Biological Pathways Combining chemistry and biology to create novel production systems. (00:27:54) From Molecules to Materials How acetyl-CoA enables fuels, plastics, and other products. (00:30:51) Teaching Biotechnology Making biotech accessible through hands-on, “just-add-water” kits. (00:33:12) Future In a Minute Rapid-fire Q&A: innovation, collaboration, and the future of biotech. (00:35:32) Conclusion Connect With Us:Episode Transcripts >>> The Future of Everything WebsiteConnect with Russ >>> Threads / Bluesky / MastodonConnect with School of Engineering >>>Twitter/X / Instagram / LinkedIn / Facebook Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Le marché du private equity traverse une période charnière. Après un cycle exceptionnel entre 2011 et 2021, le décor a changé : sorties plus compliquées, liquidité plus rare, fonds zombies, performances sous pression… et une vraie nécessité d'être beaucoup plus sélectif.Pour mieux appréhender ces mutations, Aurore Perrin reçoit Pierre-Marie de Forville, co-fondateur et CEO d'iVesta Family Office et co-fondateur de Sapians.Depuis dix ans, il supervise la sélection des fonds de private equity et rencontre au quotidien les gérants qui façonnent cette classe d'actifs. Dans cet épisode, il livre une lecture lucide (et sans tabou) du marché, des changements en cours et des clés pour investir avec plus de discernement.Découvrez :Pourquoi les fonds de private equity ont tant de mal à sortir de leurs participations, et ce que cachent les DPI qui s'effondrent.La vérité derrière les fonds de continuation, les fonds zombies et les méga-fonds.Pourquoi la performance passée n'est plus un indicateur suffisant et ce qu'il faut regarder à la place.Les conseils concrets de Pierre-Marie pour sélectionner un bon fonds et piloter son cash management.Bonne écoute ! Des ressources pour approfondir : Pourquoi et comment investir dans le private equity en 2026 https://sapians.com/blog/pourquoi-et-comment-investir-dans-le-private-equityLes 5 règles d'or pour investir en private equity https://sapians.com/blog/5-regles-pour-investir-en-private-equityFonds de continuation : guide complet pour comprendre ce mécanisme du private equity https://sapians.com/blog/fonds-de-continuationInvestir en private equity secondaire : fonctionnement, avantages, stratégie https://sapians.com/blog/private-equity-secondaire-----------------------Attention : Les performances passées ne préjugent pas des performances futures et investir comporte des risques de perte partielle ou totale en capital. Ce contenu est informatif et ne constitue pas un conseil en investissement. Toute décision doit être adaptée à votre situation. Si vous souhaitez bénéficier de conseils personnalisés, veuillez créer votre compte ou prendre rendez-vous avec un conseiller Sapians.SAPIANS - RCS n°919 330 969 - ORIAS n°23003561 en qualité de CIF et COA. Activité de démarchage bancaire et financier.

Rep. Terry Ridon speaks with Christian Esguerra on the latest COA notice of disallowance on Sara Duterte's confidential fund.

Serial entrepreneur, investisseur deep tech et ardent défenseur de la souveraineté européenne, Charles Beigbeder, ingénieur aérospatial de formation, a construit l'une des trajectoires les plus singulières de l'entrepreneuriat français, de l'intégration de satellites chez Matra à la fondation d'Audacia, maison de private equity qui gère aujourd'hui près d'un milliard d'euros d'actifs.Dans cet échange passionnant, Charles Beigbeder nous raconte :Comment il a bousculé deux marchés en situation de quasi-monopole, le courtage en ligne avec Selftrade, puis l'énergie avec Poweo, en profitant des grandes dérégulations européennesComment il a fait pivoter Audacia vers la deep tech en créant des fonds hyper-spécialisés là où il n'en existait aucun (le quantique, le New Space, la décarbonation)Sa vision sans détour sur l'Europe, sa souveraineté technologique et le retard criant de l'épargne européenne face aux AméricainsSes conseils aux investisseurs pour sortir du faux dilemme performance vs. impactBonne écoute ! Ressources complémentaires pour aller plus loin : Business Angel : guide complet pour investir dans une start-up https://sapians.com/blog/business-angel Cession d'entreprise : tout ce que vous devez savoir https://sapians.com/blog/cession-entrepriseComment investir et protéger 1 million d'euros d'héritage ? https://sapians.com/blog/investir-1-million-deuros-heritageLes clés pour investir en venture capital ou capital-risque https://sapians.com/blog/investir-venture-capital-ou-capital-risque-----------------------Attention : Les performances passées ne préjugent pas des performances futures et investir comporte des risques de perte partielle ou totale en capital. Ce contenu est informatif et ne constitue pas un conseil en investissement. Toute décision doit être adaptée à votre situation. Si vous souhaitez bénéficier de conseils personnalisés, veuillez créer votre compte ou prendre rendez-vous avec un conseiller Sapians.SAPIANS - RCS n°919 330 969 - ORIAS n°23003561 en qualité de CIF et COA. Activité de démarchage bancaire et financier.

Coa nova música da Laura Lamontagne abrimos unha nova edición do Grandes Vozes do Nosso Mundo. A seguir, o mellor da música da Galiza e do conxunto dos países de raíz galega.

ℹ️ Retrouvez les informations clés de cet épisode dans un guide condensé sur la succession, à télécharger en PDF : https://sapians.com/guide-successionPercevoir un héritage, ça ne s'improvise pas. Les délais sont courts, les décisions sont lourdes, et personne ne vous remet spontanément le mode d'emploi. Quatre mois avant que créanciers et co-héritiers puissent vous forcer la main ; six mois pour régler les droits de succession. Et entre les deux, des choix que beaucoup regrettent d'avoir mal faits. Dans cet épisode, Souleymane-Jean Galadima, cofondateur et CEO de Sapians, partage une feuille de route concrète et actionnable pour percevoir un héritage avec le moins de complications possible. Découvrez :Les 5 décisions fondamentales à prendre dans les 6 premiers mois et les délais légaux à connaître pour ne pas se retrouver pris de court.Les 3 choix qui s'offrent à vous en tant qu'héritier et leurs impacts pour votre patrimoine personnel.Les pièges bancaires, fiscaux et familiaux qui transforment une succession en cauchemar.Immobilier locatif, entreprise avec salariés, holding familiale... comment gérer l'urgence quand le patrimoine est complexe ?Ce que vous pouvez faire dès aujourd'hui, de votre vivant, pour ne pas laisser ce fardeau à vos enfants.Bonne écoute ! Des ressources pour approfondir : Transmission d'entreprise : 5 stratégies fiscales à connaître https://sapians.com/blog/transmission-entrepriseIndivision successorale expliquée : fonctionnement, droits des héritiers et risques à anticiper https://sapians.com/blog/fonctionnement-indivisionLe calcul des droits de succession, le guide pour tout comprendre https://sapians.com/blog/calcul-droits-successionComment bien rédiger sa clause bénéficiaire ? (Assurance vie, PER assurance) https://sapians.com/blog/clause-beneficiaireDonation-partage transgénérationnelle : comment transmettre directement à vos petits-enfants ? https://sapians.com/blog/donation-partage-transgenerationnelle-----------------------Attention : Les performances passées ne préjugent pas des performances futures et investir comporte des risques de perte partielle ou totale en capital. Ce contenu est informatif et ne constitue pas un conseil en investissement. Toute décision doit être adaptée à votre situation. Si vous souhaitez bénéficier de conseils personnalisés, veuillez créer votre compte ou prendre rendez-vous avec un conseiller Sapians.SAPIANS - RCS n°919 330 969 - ORIAS n°23003561 en qualité de CIF et COA. Activité de démarchage bancaire et financier.

(2:45) No Instituto de Estudos Miñoráns exhíbese "Ilustrando o Cambio Climático", unha mostra de infografías producidas por Illustraciencia e o Museo Nacional de Ciencias Naturais. Conversamos coa ilustradora especialista en visualización de datos Laura Castro Soto. (14:14) Marian Rol, directora do Laboratorio de Cronobioloxía da Universidade de Murcia, asistiu ao VI Encontro da Noite organizado pola Agrupación Astronómica Io. Os seus estudos amosan diferenzas entre Galicia e o norte de Portugal no aproveitamento da luz e nos hábitos alimentarios. (29:00) O calendario da Historia da Ciencia de Moncho Núñez lévanos ao descubrimento do hidróxeno. (30:18) Coa psiquiatra Iria Veiga, @rainhavermella, abordamos os mitos sobre a esquizofrenia. (40:09) Luís Carral (CITENI, Ferrol) preséntanos un estudo sobre a viabilidade de crear arrecifes artificiais feitos con ecoformigón de cunchas de vieira no que colaboraron os restaurantes con estrela Michelin de Galicia. Só estes establecementos producen un 12% do refugallo anual de cuncha de vieira de Galicia.

With April showers upon us, I address your Biohacking and Lifehacking questions in this rare livestream Q&A. And we chat with our chipper friend Daniel about Psalm 23 and mental health...5:40 Biohacks for OCD9:50 SKQ1 for Dry Skin14:25 COA-verified Methylene Blue?17:05 Piracetam Dosage20:15 Is Piracetam Hepatotoxic?23:20 Visoluten vs Visomitin for Macular Degeneration27:55 Nootropics Vendors in Australia31:20 Psalm 23 for mental healthRead

Investir en actions, ce n'est pas juste choisir entre le CAC 40 et le S&P 500. Derrière chaque indice, il y a des entreprises de tailles très différentes avec des logiques, des risques et des opportunités qui ne se ressemblent pas.Dans ce Focus Marchés, Aurore Perrin reçoit Nour Bendimered, Directeur des Investissements Marchés Financiers  chez iVesta, pour comprendre les enjeux propres aux segments small, mid et large caps et savoir composer son portefeuille avec discernement.Dans cet épisode, vous découvrirez : Quelles sont les vraies différences entre small, mid et large caps ?ETF ou gestion active : est-ce que le choix change selon la taille des entreprises ?Comment intégrer ces différents segments dans son portefeuille, et dans quelles proportions ?Small et mid-cap européennes : potentiel de surperformance réel ou idée reçue ?Moins d'IPO, plus de private equity... Les marchés cotés se vident-ils ? Qu'est-ce que ça change pour un investisseur ?Bonne écoute ! Quelques ressources pour aller plus loin : Comment choisir un ETF ? Découvrez nos 5 conseils ! https://sapians.com/blog/comment-choisir-un-etfQuel ETF choisir pour une allocation performante et résiliente ? https://sapians.com/blog/quel-etf-choisirGestion Passive vs Gestion Active : comment mettre en place sa stratégie d'investissement ? https://sapians.com/blog/gestion-passive-vs-gestion-activeComment fonctionne un ETF ? https://sapians.com/blog/fonctionnement-etf -----------------------Attention : Les performances passées ne préjugent pas des performances futures et investir comporte des risques de perte partielle ou totale en capital. Ce contenu est informatif et ne constitue pas un conseil en investissement. Toute décision doit être adaptée à votre situation. Si vous souhaitez bénéficier de conseils personnalisés, veuillez créer votre compte ou prendre rendez-vous avec un conseiller Sapians.SAPIANS - RCS n°919 330 969 - ORIAS n°23003561 en qualité de CIF et COA. Activité de démarchage bancaire et financier.

Roger and Annie check in mid-tax-season with a candid look at what's actually landing on desks — from W-2s showing overtime pay coded a half-dozen different ways to clients convinced their entire salary qualifies for the new deduction. They also break down the meal and entertainment changes taking effect in 2026, including why your office coffee pot is now a tax problem.SponsorsPadgett -  Contact Padgett or Email Jeff PhillipsGet NASBA Approved CPE or IRS Approved CELaunch the course on EarmarkCPE to get free CPE/CE for listening to this episode.Chapters(00:00) - Mardi Gras Catch Up (01:53) - Tax Season Pulse Check (05:17) - New Tips and Overtime Law (07:07) - Tracking and Payroll Prep (10:58) - New Fees and Tip Confusion (12:46) - W2 Example Box 14 Codes (16:25) - Should We Ask About Overtime (20:36) - OT Premium Smell Test (24:39) - Weird W2 Overtime Codes (27:04) - Pay Stub Premium Math (29:25) - Pay Stub Math Costs (29:55) - Overtime Premium Basics (32:13) - W2 Box 14 Overtime (33:27) - When Details Are Missing (35:35) - Double Overtime Limits (36:18) - Salary vs Overtime Claims (38:36) - Due Diligence and Fees (41:01) - Meals Rules Change 2026 (45:01) - Zero Deduction Office Meals (45:37) - Coffee and Snacks Debate (48:59) - Client Education and COA (51:48) - IRS Paper Checks Ending (55:49) - Wrap Up and Next Steps Follow the Federal Tax Updates Podcast on Social Mediatwitter.com/FedTaxPodfacebook.com/FedTaxPodlinkedin.com/showcase/fedtaxpodConnect with the Hosts on LinkedInRoger HarrisAnnie SchwabReviewLeave a review on Apple Podcasts or PodchaserSubscribeSubscribe to the Federal Tax Updates podcast in your favorite podcast app!This podcast is a production of Earmark MediaThe full transcript for this episode is available by clicking on the Transcript tab at the top of this pageAll content from this podcast by SmallBizPros, Inc. DBA PADGETT BUSINESS SERVICES is intended for informational purposes only.

What if the reason you’re not healing isn’t that you need another diagnosis? 0:08 It’s that your cells aren’t receiving the right signals. Because the body doesn’t run on diagnosis, it runs on 0:16 communication. And peptides are one of the most powerful, most misunderstood 0:21 tools we have for cellular signaling, immune balance, tissue repair, gut 0:27 lining support, metabolic control, brain signaling, sleep cycles, and even sexual 0:35 wellness. Today, I’m going to do what most people won’t. Define peptides in 0:41 plain English for you. break them into categories by what they’re best at and 0:47 tell you which ones are FDA approved on the list and which ones are commonly 0:53 used off label or investigational with the evidence that actually says these 1:00 work. This is going to be a powerful episode and if you’ve ever felt like you’re hearing hype without clarity, 1:07 this one’s for you. So, as usual, grab your cup of coffee or tea and settle in 1:13 as we talk about peptides that can fit into your healing journey. We’re going 1:19 to have a short word from our sponsor. You know, we got to do that. That’s how we stay on the air here. So, we will be 1:26 right back after this. Did you know sweating can literally heal your cells? 1:32I nfrared saunas don’t just relax you. They detox your body, balance hormones, 1:37 and boost mitochondrial energy. I’m obsessed with my health tech sauna. And 1:42 right now, you can save $500 with my code at healthtechalth.com/drmuthqen25. 1:54 All right, here we go, guys. I am excited to dive into peptides with you. 2:00 So understanding peptides is foundational, right? And I’ve been 2:06 studying peptides now for about nine years. Um, and I find that they are 2:13 incredible. Um, so I want to break down for you what peptides actually are, what 2:19 they do, and some of the top peptides that are available today, and how they 2:25 can be utilized. Because I think it’s really important. And I think it’s it’s there’s a lot of confusion out there about what these things actually are and 2:32 are they safe? Are they not? When do we use them? What’s the science behind them? So, we’re going to dive in and 2:38 we’re going to talk about all things peptides. So, let’s get ready here. Here we go. So, peptides are short chains of 2:45 amino acids and they typically range anywhere from 2 to 50 amino acids and 2:51 they’re linked by peptide bonds. So think of them as the superglue that holds the amino acids together. They sit 2:58 between the amino acids and they are full proteins in terms of their size and 3:04 their complex structure. And what makes peptides particularly interesting in 3:10 medicine is their role as signaling molecules. They’re essentially the 3:15 body’s text messages carrying specific instructions to cells and tissues. And 3:21 unlike our proteins which often serve as structural roles or act as enzymes, 3:28 peptides typically function as hormones, neurotransmitters and growth factors and 3:33 they bind to specific receptors on the cell’s surfaces or within the cells and 3:39 they trigger this effect. It’s like a cascade effect of a biochemical reaction 3:45 that ultimately changes the cellular behavior. So basically, it’s changing 3:50 the way the body’s cell structure acts. And this is why peptides can be so 3:56 incredibly powerful and therapeutic when you introduce the right peptide signal. 4:02 Now, you could theoretically redirect cellular processes toward healing, 4:07 towards metabolism, immune balance, tissue repair. Any of those things can 4:14 be manipulated to do a certain thing once we add the peptide. The challenge 4:19 in peptide medicine though lies in distinguishing between those peptides that have been rigorously studied, 4:26 proven safe and effective and approved by regulatory bodies like the FDA versus 4:31 those that exist in what we call the gray zone of a promising clinical data. 4:36 But they really lack human validation so far. And this distinction is critical because the presence of a plausible 4:43 mechanism does not guarantee safety or efficacy in living humans. So, this is 4:50 really important and we’re going to dive in and look at some of the research on all of these different peptides that are 4:56 available and I’m excited to say there’s some amazing peptides being studied right now that unfortunately are not 5:01 available. But I can’t wait to see them hit the market for us because it is going to be a gamecher as far as health 5:09 and longevity. So there is a quality control issue and there is a hidden 5:14 variable in peptide medicine with this and it’s one of the most underappreciated aspects of peptide 5:21 therapy particularly for non-FDA approved peptides. It’s quality control. 5:26 When we discuss pharmaceutical medicines, we take for granted that the pill contains what the label says. Not 5:32 always true depending on where it comes from. You guys, if you’ve heard my episodes before talk about how many of our medications are made in China and 5:41 have been contaminated with other things, you will realize that that is not always true. So, just because it has 5:48 the FDA stamp of approval on the medication, it still does not necessarily mean it’s safe and we still 5:54 need to do our homework on it. So, sorry for digressing on you guys, but you know, when we get a medication, we we 6:00 think that what the amount says is what is there, doesn’t have contaminants, it’s manufactured with good 6:06 manufacturing practices. You’ll see that listed as GMP on the bottle, and it’s been stored properly, it’s been 6:12 maintained stable, and with research peptides and compounded formulations, 6:17 none of this can be assumed. So, I will share a story with you. There was a gentleman that was purchasing these 6:24 peptides online from a research facility and um did not know that they were 6:30 coming from China and he was ordering a particular growth hormone peptide and 6:35 after a little while he had he had done fine for the few first few bottles. After a little while he started having 6:42 some complications. He started getting really irritable and angry and ragy and 6:47 he didn’t quite know what was going on. And so he decided to go get some testing done. He had some blood testing done and 6:53 his testosterone level was over 5,000. So for those of you who know what testosterone level should be for a guy, 7:00 they really shouldn’t be any higher than about 1,00200 would be absolute max that we’d want to see. Now he was taking 7:06 testosterone but not to that degree. And prior to adding this peptide, his 7:12 testosterone was very stable. What they ended up finding out was the peptide that he was getting, whoever was 7:18 manufacturing it added testosterone to the peptide. They felt like if if it had growth hormone, that was great, but if 7:25 it had growth hormone and tes testosterone, all the better. And he didn’t know that. And this is the 7:31 problem that we can have with peptides if you don’t source them properly. if you’re not working with somebody that 7:37 knows how to source them and can prove that they are what they say they are. Um, I’m sure there’s a whole bunch of 7:42 studies out there too of people getting these peptides and paying hundreds of thousands of dollars for them over their 7:48 lifetime and finding out they were nothing more than just sterile water. So, you really do need to be careful 7:53 with your quality control. Now, this kind of leads us right into the next topic that we’re going to talk about and that’s the manufacturing question, 8:00 right? The FDA approved peptides are manufactured in facilities subject to 8:05 the FDA inspection rules following our GMP regulations and these facilities 8:11 must validate their manufacturing process, demonstrate consistency batch to batch, test for purity and potency. 8:18 They need to test for bacterial endotoxins and sterility and they need to maintain detailed records. So, when a 8:25 pharmaceutical company submits a drug application, the FDA inspects the manufacturing facility as part of the 8:32 approval process. If you’re getting peptides from a different country, none of that is happening. And there are some 8:38 ways for us to determine if that is what you’re getting. Typically, the rule of thumb is if your peptides are coming 8:44 with a different colored top, every one of them has a different colored top. Those are typically being sourced out of 8:49 China. I wouldn’t say that’s 100% but that’s kind of the rule of thumb that people follow. So compoundingies these 8:56 are thearmacies that make our bio identical hormones. They can make medications in any dose or strength or 9:02 route. There are thousands of them in every not that not in every state but 9:08 there are thousands of them around the country right now. So these compoundingies are registered as 503A 9:15 facilities. They do traditional compounding for individual prescriptions, right? Like they can make 9:20 thyroid, they can make LDN, they can make estrogen. You can also have a 503b 9:27 facility, which is an outsourcing facility. And these companies produce larger batches of products. They’re they 9:34 have some oversight, but they’re less stringent than for FDA approved 9:40 manufacturers. And state boards of pharmacy regulate a 503A pharmacy. And 9:45 the FDA can inspect the 503b facility, but doesn’t preapprove any of their 9:52 compounding products. So, they can inspect it, but they don’t approve them. So, research chemicals and these 9:58 suppliers operate essentially with no oversight. They explicitly market products for research use only, not for 10:06 human consumption to avoid FDA regulation. If they put that on their 10:12 product, they don’t have to comply to what the FDA is saying. And there is no required manufacturing strategies or 10:19 standards, no required testing, no required sterility assurance, and no enforcement mechanisms if products are 10:26 mislabeled or contaminated. So basically, they don’t have the liability, but that doesn’t mean that 10:31 all of them are badies or bad suppliers. It just means they don’t have to comply 10:37 to the FDA rules. Now, there are many of these companies that I’ve seen and I’ve talked to that do do a lot of this. They 10:44 do test their product for sterility. They do test their product to make sure it is what it says it is. They don’t 10:51 have to, but they do. So, if you’re going to decide to use a company that 10:56 has research only, not for human consumption, at least ask for their 11:02 proof of testing so that you know that the product you’re getting is what it says it is and that it’s clean. Because 11:08 this is where we run into the problem is in purity. So in purity peptide 11:13 synthesis can produce not just the targeted peptide but also related 11:19 peptides with deletions, substitutions, truncations or truncations of amino 11:25 acids. Sorry. And this high performance liquid we call it uh chromatography can 11:30 separate these related impurities and quality and quantify the actual target 11:35 of the peptide content. So a certificate of analysis is what you want to ask these companies for. This shows the HPLC 11:44 the testing mechanism with greater than 95% or ideally 98% purity which 11:51 indicates a higher quality product. So this certificate of analysis can be fabricated may not represent the 11:57 specific batch being sold. It happens. We need to know not everybody is honest. Not everybody, you know, does what they 12:03 say and it does what’s right. But at least you at least they’re giving you something and you have some security. 12:10 and then choose a company that was referred to by someone else that has done some homework as well. In in 12:16 commercial research, there’s independent testing and they research peptides and this has been really shocking 12:23 variability that they’ve seen. Some products contain 50% or less of the 12:29 claimed peptide and some contained primarily degradation of the product or manufacturing impurities and some 12:36 contained bacterial endotoxins at levels that could cause fever and systemic 12:42 inflammation if it was truly injected. And I would also worry with some of those problems, you know, depending on 12:48 what impurity or bacterial endotoxin was there. If you’re using a product to boost your immune system and your immune 12:54 system is already compromised, these bacterial endotoxins can actually make you sicker instead of what you want it 13:02 to do, which is making you better. So, sterility is always an issue with anything that is manufactured, 13:08 especially things that we’re doing as an injection. Peptides are intended for injection. They must be sterile. They 13:16 must be kept safe. And pharmaceutical manufacturers conduct this sterility testing on every batch. 13:22 Compoundingarmacies should conduct sterility testing particularly for high-risisk compounded 13:28 sterile preparations and research chemical suppliers may or may not conduct any testing. So injecting 13:35 non-sterile material can cause local infections, abscesses at the injection 13:41 site and or if the bacteria enters the bloodstream could potentially be 13:46 life-threatening and you could have sepsis. Now, excuse me. We saw this 13:52 happen in a compounding pharmacy uh gosh, it’s probably been 10 years ago 13:57 now, I think. um they unfortunately had a strep uh contamination in their 14:03 product and they weren’t testing it. It was a large compounding pharmacy out of Florida and they were making products 14:08 that were being injected into the joints and um these people got very very sick 14:14 and some of them died and um some of them got very very injured by this uh 14:21 complication that happened. So it’s not like this doesn’t happen. It does, but it doesn’t happen often. And that’s what 14:28 we have to know about. And so, when we’re talking with you guys about storage and stability, it’s really 14:34 important to make sure you maintain your peptides well. So, many peptides are unstable at room temperature. They 14:41 require refrigeration or freezing. We tell everyone to make sure you’re refrigerating your peptides. That way, 14:48 there’s no question about it. when it stays cold um it prevents or slows down 14:54 the process of uh bacteria growing in it. So some of these peptides actually 14:59 degrade very rapidly in the solution and they must be reconstituted immediately before use and reconstitution of the 15:07 peptides really has limited stability often just days to weeks not months. So 15:13 improper storage, temperature, um changes during shipping or prolonged 15:19 storage of a reconstituted product can lead to degradation into inactivity or 15:25 potentially even a harmful breakdown of the product itself. So if you have a product that’s been sitting in your 15:30 refrigerator for a month or two months or 3 months or 6 months, just throw it away. It’s not going to be any good. 15:37 you’re not going to actually get the peptide and the uh potency that you’re looking for anyway out of it and the 15:44 potential of you introducing an endotoxin, a bacterial endotoxin is quite high at that point. So you just 15:50 really don’t want to take the risk, excuse me. So what practitioners, what 15:56 should we do and what should patients do? Well, for any peptide therapy, we 16:03 want to source our verification. know where the peptide product comes from. Is 16:08 it an FDA approved product? Is it a 503b compounding? A research chemical 16:14 supplier? Is there a certificate of analysis? Request and review this COA. 16:20 And you want it to show purity greater than 95% but ideally greater than 98%. 16:27 You want that identity be identity to be confirmed by mass spectromedy. Uh 16:33 sterility testing should be done. Bacterial endotoxin testing should be done. Batch number matching of the 16:39 product that you received should be done. Proper storage. You want to know that this has been refrigerated or 16:46 frozen as directed once it’s been mixed. Look at the expiration dates for reconstituting your peptides. Track that 16:53 reconstitution date and discarded accordingly like we just talked about. Monitor for your adverse effects. Even 17:01 with the perfect quality control, monitoring for adverse effects is essential with questionable quality and 17:08 vigilance is really critical here. I know it’s frustrating for a lot of patients when they have to get several 17:15 bottles and they only last a week or two. right here, you guys. This is why 17:21 they only last a short period of time because once they’re mixed, they start 17:26 to degrade and they won’t be good and you won’t get the benefit from it. So, 17:31 it’s really important with these research peptides specifically, practitioners should recognize that all 17:38 recommending products without quality assurance violates the fundamental medical principle of first do no harm. 17:45 If a patient is determined to use research peptides despite counseling, providing guidance on quality 17:52 verification, requesting those COAs, using pharmaceutical grade sources when available, proper testing, this all 17:59 reduces harm, but doesn’t constitute necessarily that recommendation. Now, 18:06 that being said, today it’s very difficult to find peptides by the compoundingies because of what the FDA 18:13 has done. So most of the peptides that are available to us have been labeled 18:18 not for human consumption, not because they’re not good products, but because 18:25 of what the FDA did. And this is how these companies have been able to 18:31 continue to provide peptides to the medical community. And if you know you 18:36 have a good company, then you’re, you know, you’re still taking the risk, right? But at the end of the day, the 18:42 reason they’re doing that is to protect themselves from the FDA, from liability. Um, so just kind of know that there is 18:50 some talk in the community with um Bobby Kennedy that this is going to change and 18:55 they are going to bring peptides back to the compounding pharmacies. Now, we don’t know which ones they’re going to 19:01 bring back. Uh, will it be all of them? Will it just be some of them? What’s going to happen here? Um, is it going to 19:07 go to the pharmaceutical companies like our GLP1s did? We don’t know what that’s going to look like quite yet. Um, but it 19:14 is coming and that is positive news. So, let’s talk now about FDA approved 19:21 peptide medications. So, this is the metabolic revolution, right? GLP1 19:28 and our dual increeting agonists. This is an exciting time. GLP-1s are amazing. 19:35 Um, a lot of people are skeptical, a lot of people love them, a lot of people hate them. Whichever side of the fence 19:42 that you’re on, I understand. But I want to talk about the science of it today 19:48 and what it actually means for people. So, the story of GLP1 glucagon like 19:54 peptide one represents one of the most significant advances in metabolic 19:59 medicine in the past several decades. GLP-1 is an accretin hormone. It’s 20:05 gutder derived peptide that potentiates insulin secretion in response to food 20:11 intake. And the body naturally produces GLP-1 in the intestinal L cells, but it 20:17 rapidly degraded by the enzyme DPP4 giving it a halflife of only about 2 20:24 minutes. So this rapid breakdown made in therapeutically impractical until 20:31 research was developed and modified the analoges that resist the enzyme degradation. So for those people who 20:39 never feel full when they’re eating, never feel satisfied when they’re done, this is because their body is either not 20:46 producing enough GLP1 or it’s not getting the signal right. And this is a 20:51 leptin issue. This is an insulin issue. It’s a GLP-1 issue. It’s a complicated 20:56 issue. This is not anything that the person is doing wrong. It’s what is happening to their body. And so GLP1s 21:03 have really revolutionized this. So one particular GLP-1 that we have is 21:09 semiglutide. And this GLP-1 agonist is what changed everything in the world of 21:16 metabolic medicine. Semiglutide is marketed as ompic for type 2 diabetes 21:23 and it’s marketed as WGOI for chronic weight management. It is a modified 21:29 GLP-1 analog with 95 or sorry 94% amino acid sequence uh homology to human 21:37 GLP-1. So it means that it’s it’s just like our own GLP-1 that we make. This 21:42 modification includes specific amino acid substitutions and the addition of C18 21:50 a fatty acid chain which allows the peptide to bind to albumin. Now this 21:56 albumin binding dramatically extends the half-life to approximately one week 22:01 enabling one weekly dosing which is a major advantage over the earlier GLP-1 22:07 agonists that require daily or twice daily injections. The mechanism by which 22:13 semiglutide works is multiaceted. At the pancreatin level, it binds to GLP-1 22:20 receptors on the pancreatic beta cells enhancing glucose depending sorry 22:27 enhancing glucose dependent insulin secretion. This glucose dependency is 22:33 crucial. It means the peptide only stimulates insulin release when blood glucose is elevated. This dramatically 22:41 reduces the hypoglycemic risk compared to insulin or even uh sulfuras. 22:47 Simultaneously semiglutide suppresses glucagon secretion from pancreatic alpha 22:53 cells further improving glycemic control. This is really amazing because 23:00 over the years when we’ve used insulin, which is also a peptide by the way, you 23:05 had to dose it just right because if you didn’t, you would produce so much insulin that it would crash the blood 23:12 sugar and then somebody would have too low of a blood sugar. They’d be hypoglycemic and they’d have to eat more 23:18 sugar and then they’d have to modify the insulin again and the person would be going up and down, up and down, up and 23:24 down all day long. And that created a lot of problems for people and so this 23:30 helps to stabilize that so it is not such an intense change. Now in the GI 23:36 tract semiglutide delays the gastric emptying particularly pronounced during 23:41 the initial weeks of therapy. This slowing of the gastric emptying contributes to the sensation of being 23:48 full and early satiety that patients often describe. However, this effect 23:54 tends to attend to weight over time as the body adapts through the appetite 24:00 suppressing effects generally persist through central mechanisms. So, when we 24:05 talk about what is actually happening, we’re slowing that digestive process down. That’s why people aren’t so 24:11 hungry. It’s why they’re not eating so much. This is why people can develop constipation with these products because 24:17 it’s slowing the body’s digestive tract down. Now some people will call this 24:22 gastroparesis. Um gastroparesis is actually different. 24:28 It is when we lose control over what’s happening in the in the colon like the 24:34 nerves and things like that just stop working. I have never seen that with the GLP1s that we prescribe in micro doing. 24:42 um it’s been documented. It can happen, but again it a lot of it is dosing and a 24:48 lot of it is staying on top of your client and what’s happening and what’s going on and what you’re doing and making sure that they do have good 24:54 motility still. So a lot of these things can be mitigated if you have problems 24:59 with them. Now one of the most profound effects of semiglutide occur in the 25:05 central nervous system. GLP-1 receptors are widely distributed in the brain 25:10 particularly in the hypothalamus and the brain stem area where we are involved in 25:15 appetite regulation. So when when wilding and colleagues published their 25:20 landmark step one trial in the New England Journal of Medicine in 2021, 25:25 they demonstrated that participants receiving 2.4 4 milligrams of semiglutide weekly achieved an average 25:32 weight loss of 14.9% of their body weight over 68 weeks. Now, I want you 25:39 guys to really understand this. We’re talking roughly 15% body weight loss 25:45 over a year, longer than a year. 52 weeks is a year, right? This is 68 25:50 weeks. So, it took longer for them to lose. We’re not talking about giving 25:55 somebody a dose to lose 15% of their body mass in a month or two. That that 26:01 is not healthy for any of us. That is not what we’re talking about doing here. Now, they compared this to placebo and 26:08 the placebo was only 2.4%. So, that is a significant difference. 26:14 And even beyond the numbers, patients reported something very qualitatively different, a reduction in what’s now 26:21 called food noise. Everybody knows what food noise is. We’ve talked about this long before GLP1. It’s that craving. 26:28 It’s that part of your brain that just keeps thinking about I want to eat something. You know, that was actually 26:34 reduced and they didn’t expect to see that happen. Now, this refers to the constant mental preoccupation with food, 26:42 the intrusive thoughts about eating, the difficulty in feeling satisfied. Semi-glutide appears to appears to 26:49 modulate reward pathways in the misolyic system reducing hedonic eating and food 26:57 cravings. Now there are also great cardiovascular effects of semiglutide 27:02 that extend beyond weight loss. Uh the sustained six and select trials 27:07 demonstrated significant reductions in major adverse cardiovascular events uh 27:14 mace in high-risisk populations. The select trial published in 2023 showed 27:20 that semiglutide reduced cardiovascular death, non-fatal myioardial inffection 27:25 and non-fatal stroke by 20% in adults with overweight or obesity and 27:31 established cardiovascular disease but without diabetes. So this suggests that 27:37 mechanisms beyond glucose control and weight loss possibly including 27:42 anti-inflammatory effects, improvements in endothelial function and favorable 27:47 changes to lipid profiles. Now I will tell you the clients that I work with that are on GLP1, 27:53 they will tell you that their inflammation has been significantly reduced. We are also seeing really 28:00 amazing results in lipid profiles. um part of its weight loss, but there is a 28:06 component to this that is lowering the triglyceride levels because it’s related to sugar and how the body’s processing 28:11 it. And we’re seeing better profiles, less need for statins as a result of 28:17 that. If if you want to listen to my episode on statins, I have one on that. Uh they are not my favorite medication. 28:24 I think it’s overprescribed and overused um and not really affecting or 28:29 addressing the problem. So these things can really be helpful. There’s also some 28:34 uh ramblings going on with GLP-1s saying that they may be able to help with 28:40 addiction in the future because of where they’re finding it affecting the brain and how it affects the food noise and 28:47 the cravings that we have for food and the addiction for food. Could it potentially help with other addictions 28:53 down the road? We’ll have to wait and see on that one. So semiglutide’s FDA prescribing information also includes a 29:00 box uh boxed warning about thyroid sea cell tumors. So in rodent studies 29:06 semiglutide caused dose dependent and treatment duration dependent sea cell 29:12 tumors at clinically relevant exposures. So while it’s unknown whether or not 29:17 semiglutide causes uh thyroid cancer tumors in humans and the rodent thyroid biology 29:26 differs significantly from humans, the drug is contraindicated in patients with a personal or family history of 29:33 medillary thyroid carcinoma or in patients with multiple endocrine neopl neoplasia syndrome type two. it is 29:42 uh contraindicated for safety effects with that. Um I have seen endocrinologists okay GLP1s to be used 29:50 in patients who’ve had other forms of thyroid cancer just not the meillary 29:55 thyroid cancer. So there is possibility there. Now the most common side effects 30:00 are gastrointestinal. It’s nausea affects about 20 to 44% of patients 30:06 depending on the formulation with diarrhea, vomiting, constipation, abdominal pain, and also frequently 30:13 reported in clinical trials. I see this in my clinic, too, especially dose dependent. Um, and it happens early on 30:20 when you’re first starting the medication, but seems to settle out over time. The one that I would add to this 30:26 that I don’t think they have on here is an increase in acid reflux. We also see that quite often uh especially in people 30:33 who suffer with acid reflux to begin with. Now these effects are typically most 30:40 pronounced during the escalation and they like I said often improve over time 30:45 but more serious but less common adverse effects include acute pancreatitis. 30:51 The medication needs to be discontinued immediately if this is confirmed. You can see some diabetic retinopathy 30:57 complications in patients with pre-existing retinopathy and acute kidney injury. Um, this usually happens 31:05 secondarily to dehydration from the GI effects. There are some gallbladder disease um that can occur and people who 31:13 have a sensitive gallbladder will describe uh discomfort with that. I’ve 31:18 even seen some people who’ve had their gallbladder out on GLP1s at the higher doses complain of similar pain that they 31:25 used to have when their gallbladder was in. So, really important to just kind of monitor these symptoms and work closely 31:32 with somebody that understands them and can be on top of them quite quickly if this happens. Excuse me. From an 31:39 integrative medicine perspective, semiglutide really represents a powerful tool, but it’s not a standalone 31:46 solution. Remember, the medication addresses one aspect of the metabolic dysfunction, the signaling systems 31:53 controlling appetite and glucose homeostasis, but it doesn’t address the root cause that led to the metabolic 32:00 disease in the first place. Patients who rely solely on the medication without addressing the ultrarocessed food 32:07 consumption, the ccadian disruptions, the chronic stress, the sleep apnea, or 32:12 underlying hormonal imbalances often experience weight regain when the medication is discontinued. 32:20 The drug is also not a substitute for addressing the emotional and psychological drivers of eating 32:26 behavior, including the unresolved trauma that may manifest as emotional eating. I think this is really important 32:33 because we don’t address the trauma issue enough with clients and we need to 32:38 be looking at that. There is a huge trauma effect out there these days that is I don’t want to say leading to or 32:45 causing but it is definitely contributing to chronic illness and it’s not being talked about enough. So we 32:52 really need to be talking about this and addressing this trauma aspect. Now the next GLP that one that I want to talk 32:59 about is trespathide. This is a dual agonist. It takes center stage. It is my 33:05 favorite GLP one. Trisepatide is marketed as Mangjaro for type 2 diabetes 33:11 and Zepbound for chronic weight management and it represents the next 33:16 evolution in increantbased therapy. This is a dual agonist a 39 amino acid 33:23 synthetic peptide structurally based on the human glucose dependent insulin tropic peptide so GIP sequence but 33:31 modified to activate both the GIP receptors and the GLP1 receptors. So the 33:37 addition of the GI GIP agonism to the GLP1 agonism appears to create this 33:46 synergistic effect that goes beyond simply adding the two mechanisms together. So the GIP like GLP-1 is an 33:55 increant hormone secreted by what is called the K cells in response to nutrient intake. It enhances glucose 34:02 dependent insulin secretion but it also effects on atapost tissue metabolism 34:09 potentially improving the insulin sensitivity in fat cells and influencing 34:14 how the body stores and metabolizes fat. So some research suggests that GIP may 34:20 also have effects on energy expenditure though this remains an area of 34:26 investigation. So basically what we’re saying is this drug may actually help 34:32 people who are insulin resistant or insulin sensitive, not just somebody who 34:38 has problems with glucose control. So, this is super exciting because it opens 34:43 up the door for all of these people for decades that we’ve been trying to manage with insulin resistance and trying to 34:50 prevent diabetes and honestly most of the time have been unsuccessful 34:56 unless you can keep your diet at 50 grams of carbs or less a day, which is extremely difficult. Um, and take some 35:04 supplements that may or may not work and or take some metformin that may or may not help. this drug actually really 35:11opens that up and helps in that capacity. So there was a clinical trial 35:17 called the surmount clinical trial which demonstrated that trespathide produces 35:22 even more substantial weight loss than semiglutide. In the surerount one trial published by uh J tree I might have said 35:31 that wrong. I apologize if I slaughtered your name and colleagues in the New York England Journal of Medicine in 2022. 35:38 Participants receiving the highest dose of trespide, which is 15 milligrams, achieved an average weight loss of 20.9% 35:47 of their body weight over 72 weeks, compared to 3.1% with placebo. This 35:54 level of weight loss approaches what’s typically only seen in beriatric surgery. So, this is amazing because if 36:02 this medication works and we don’t have to do beriatric surgery, stomach stapling basically, um, oh my gosh, it’s 36:11 amazing. There are so many complications and risks that go with stomach stapling and the different procedures that they 36:17 do these days. People don’t absorb their nutrients properly. They have to do liquid nutrients. It’s very complicated. 36:24 It’s very challenging. Many of these people gain their weight back. Um, and 36:30 this procedure is not fun to go through. So, if we could change that and change 36:35 the lives of people who’ve really been struggling, it is amazing. And I will tell you that I have seen this work. I 36:42 have seen people lose 100 150 pounds on these medications over a year or two 36:50 period of time. It is definitely slower than beriatric surgery on some standpoints, but that is okay. You don’t 36:56 want that rapid weight loss. It’s not good for you. It’s not healthy for you. It doesn’t look well. You know, we want 37:03 to do this safely and effectively in the best way that we can possibly do that for you. Now, the adverse effect profile 37:10 is similar to semiglutide. It’s dominated by gastrointestinal effects. 37:15 Nausea, diarrhea, decreased appetite, vomiting, constipation. These were all commonly reported in the surmount 37:22 trials. And like semiglutide, tricepide carries a blackbox warning regarding the 37:27 thyroid sea cell tumors based on the rodent data and it shares the same contra indications in patients with a 37:34 family history of thyroid cancer and men too. So the mechanism behind why 37:40 tepatide often produces more substantial weight loss than GLP-1. The agonism 37:45 alone remains under investigation, but it may relate to the complimentary effects on the different aspects of 37:51 energy homeostasis or to GIP’s effects on atapost tissue and potentially on 37:58 central central nervous system pathways that GLP1 alone doesn’t fully address. 38:03 Now patients often report even more profound reductions in food noise with tricepide compared to GLP1 and uh sorry 38:12 GLP1 the agonists through this is anecdotal and hasn’t been regularly 38:17 quantified in quality studies. So I’ve done both uh personally and in my 38:22 practice. I really like trespide better than semiglutide. For me I had too many side effects with semiglutide. uh I had 38:30 less side effects with trespathide. I also plateaued on semiglutide which I 38:35 didn’t really care for. And with Tresepide, I haven’t plateaued and I’ve been able 38:42 to lose about 25 pounds in um a year and a half and I’ve been able to maintain 38:49 that. Um and I continued to use it because I do have a strong family history of cardiovascular disease. And 38:56 if this could help me so that I don’t follow my family lineage with cardiovascular disease, I am all for 39:03 trying to do that. I’ve watched too many of my family members suffer from this. I’ve lost my dad at a very young age. I 39:09 lost my grandfather at a young age to it. All of their brothers to this. And I don’t want to be that same person. So 39:16 that is why I chose to do that. And I think it’s really important for us to take a look at that and understand that. 39:24 Now, I know this has been a really long podcast and I don’t typically do podcasts this long. I have a whole host 39:31 of information on additional peptides. So, I’m going to break this up for you 39:36 guys and I’m going to do another episode and we’re going to pick up where we left off here with these peptides so that we 39:43 can actually start to dive into different peptides as well. So, check 39:48 out my next podcast show when we’re going to dive into the peptides that 39:54 talk about sexual wellness, immune function, and all the other cool things 39:59 that we can do with peptides. So until then, remember to like, share, and 40:04 subscribe. It really helps us get out to other people and share our information, 40:10 and join us for our next episode as we continue the talk about peptides. 40:15 Welcome to Let’s Talk Wellness Now, where we bring expert insights directly to you. Please note that the views and 40:21 information shared by our guests are their own and do not necessarily reflect those of Let’s Talk Wellness Now, its 40:28 management, or our partners. Each affiliate, sponsor, and partner is an 40:34 independent entity with its own perspectives. Today’s content is provided forformational and educational 40:40 purposes only and should not be considered specific advice, whether financial, medical, or legal. While we 40:48 strive to present accurate and useful information, we cannot guarantee its completeness or relevance to your unique 40:56 circumstances. We encourage you to consult with a qualified professional to address your 41:01 individual needs. Your use of information from this broadcast is entirely at your own risk. By continuing 41:08 to listen, you agree to indemnify and hold Let’s Talk Wellness Now and its 41:14 associates harmless from any claims or damages arising from the use of this 41:20 content. We may update this disclaimer at any time and changes will take effect 41:26 immediately upon posting or broadcast. Thank you for tuning in. We hope you 41:31 find this episode both insightful and thought-provoking. Listener discretion 41:36 is advised.The post Episode 256 – How Peptides Work, Benefits, and FDA-Approved vs Off-Label Use Explained first appeared on Let's Talk Wellness Now.

Desde o pub Macondo da Coruña coa música ao vivo do piano de Juanjo Fernández realizamos o noso repaso á mellor ciencia do ano. Coa participación dos nosos colaboradores Marta Vila, Susana Ladra, Deborah García Bello, Estíbaliz Espinosa e Xabier Pérez Couto. Parte 2.

Desde o pub Macondo da Coruña coa música ao vivo do piano de Juanjo Fernández realizamos o noso repaso á mellor ciencia do ano. Coa participación dos nosos colaboradores Marta Vila, Susana Ladra, Deborah García Bello, Estíbaliz Espinosa e Xabier Pérez Couto. Tamén conversamos con Manuel Díaz de Sotavento, que nos debulla o achado do ano. Parte 1.

What is Pure Michigan actually built to do?Pure Michigan is not a “wake up and conquer the world” strain. It's usually a heavy hybrid that leans indica in feel, built more for depth than sparkle.This cultivar is commonly bred from Oreoz x Mendo Breath, which already tells you something. Both parents are known for dense structure, rich flavor, and body-forward effects.From Beehive Farmacy, batch specifics always matter, so check your label. But here's what Pure Michigan typically looks like chemically.• THC often in the high teens to mid 20 percent range• Very low CBD• Minor cannabinoids like CBG sometimes present in small amountsTranslation: this is THC dominant. If your tolerance is low, it can get heavy fast. This is not a microdose-first strain unless you intentionally keep it that way.Common dominant terpenes in Pure Michigan:• Caryophyllene• Myrcene• LimoneneCaryophyllene is the spicy, peppery terpene that also interacts with CB2 receptors, often associated with body relief.Myrcene leans sedating in higher concentrations.Limonene can add a slight mood lift or brightness.When myrcene and caryophyllene sit high together, you usually get that “deep exhale” body experience. Muscles loosen. Thoughts slow. The edges soften.Not guaranteed. But that's the tendency.At moderate doses:• Strong body relaxation• Slower mental pace• Warm, heavy calm• Possible couch gravityAt higher doses:• Sleep pressure• Brain fog• Hard pivot into “I'm done for the night”This is typically not a strain people use for high productivity. It leans evening. Recovery. Decompression.Who is this for:• People looking to wind down• Evening use• Body tension• High stress daysWho should be cautious:• Anyone sensitive to sedation• Anyone needing mental sharpness• New consumers jumping straight into large dosesThe real takeaway here is this: Pure Michigan is more about weight than sparkle. If you're chasing heavy body calm, it usually delivers. If you're chasing clarity and energy, this probably isn't your lane.And like we always say, strain names are branding. The batch chemistry is the truth. Always read the COA. Always start lower than you think.Utah cannabis makes more sense when you stop chasing names and start reading numbers.Keep the Mic on.Fuel the movement. Keep the conversation going.We keep a running list of tools and brands we personally enjoy and actually use.Find everything in one place here:

On this Kaya Cast episode, host Tommy Truong chats with Jason Reposa, founder of Good Feels, the team behind the Good Vibes fast-acting tinctures and hemp beverages. Jason shares his founder journey—from selling a media business to embracing a mission-driven cannabis tech company—and how a focus on liquid formats delivers fast, precise dosing across high- and low-dose customers. Learn how Good Feels evolved from early beverage experiments to a syrup-based, drink-friendly delivery that can be dosed from 5 mg to 1000 mg per one-ounce bottle, with onset in roughly 10–15 minutes. The discussion covers product iteration, taste optimization, and the balance between consumer education and regulatory realities in Massachusetts, including hemp versus cannabis rules and COA transparency. Jason offers candid perspectives on marketing versus sales, in-store partnerships, sampling strategies, and the need for strong branding to stand out in a crowded market. If you're a dispensary owner, buyer, or brand founder, you'll gain actionable insights on product development, category positioning, retailer partnerships, and building a brand that makes people feel good—and empowers them to do more good. Find out more about Good Feels at:https://getgoodfeels.com/https://www.linkedin.com/in/jasonreposa/https://www.linkedin.com/company/good-feels/ 00:00 Introduction and Guest Background00:29 Journey into the Cannabis Industry01:37 Product Development and Market Reception03:34 Personal Motivation and Business Evolution13:33 Challenges and Innovations in the Beverage Market22:32 Marketing Strategies and Consumer Insights30:33 Target Audience: High Dose Consumers31:59 Product Development Journey33:24 Challenges in the Cannabis Market35:49 Product Improvement and Feedback39:55 Cannabinoid Innovations and Regulations46:55 Marketing and Retail Partnerships53:40 Rapid Fire Questions and Personal Insights57:13 Mission and Vision of Good FeelsKaya Cast podcast, Kaya Cast episode, cannabis business podcast, cannabis industry podcast, hemp beverage podcast, fast acting cannabis tinctures, liquid cannabis dosing, fast onset THC products, fast acting hemp drinks, cannabis beverage innovation, cannabis tincture technology, liquid cannabis delivery systems, precise THC dosing, low dose THC products, high dose THC tinctures, microdose cannabis products, high potency hemp tinctures, syrup based cannabis beverages, drink friendly cannabis syrup, 10 to 15 minute onset cannabis, fast acting hemp tincture Massachusetts, cannabis beverage market trends, cannabis product development insights, cannabis founder journey, cannabis startup story, mission driven cannabis brands, cannabis branding strategy, cannabis category positioning, dispensary product buying insights, dispensary buyer education, cannabis retail partnerships, in store cannabis sampling strategies, cannabis sales versus marketing, cannabis consumer education, cannabis regulatory compliance Massachusetts, hemp versus cannabis regulations MA, cannabis COA transparency, hemp COA compliance, cannabis beverage dosing accuracy, cannabis tincture taste optimization, cannabis product iteration process, cannabis innovation leadership, cannabis beverage manufacturing, hemp beverage formulation, cannabis syrup formulation, cannabis liquid formats, cannabis drink additives, cannabis wellness beverages, functional cannabis drinks, cannabis brand differentiation, standing out in cannabis retail, dispensary shelf strategy, cannabis merchandising insights, cannabis buyer decision making, cannabis retailer partnerships US, cannabis distribution strategy Massachusetts, Massachusetts cannabis market insights #kayacast #cannabis #tips #dispensaries #business #podcast

ABOUT THE EPISODEListen in to a special interview as COA's David Schrock and Stephen Wellum are joined by Steve Deace to talk about the best way to strategize and save lives, including a breakdown of the state of the Pro-Life and Abolitionist movements.Timestamps00:42 – Intro05:16 – How Do We Think About Incrementalism & Abolitionism? What is Most Effective?13:30 – What are Steps We Can Take to Disciple Zealous Brothers?22:17 – What is Recommended for Our Churches?26:57 – What Media is Most Effective in This Battle?30:50 – The Groundwork that Must Be Laid32:36 – What Would You Say for Pastors Who Consider This Too Political?36:27 – OutroResourcesThe Steve Deace ShowThe SBC's Turning Point (ft. Steve Deace) – Center For Baptist LeadershipTheme of the Month: Abolishing Abortion, Advocating for LifeGive to Support the Work

Accreditation can feel overwhelming, but when done well, it's not a once-every-ten-years scramble. Dr. Angie Mund joins us this week to help reframe accreditation as an ongoing leadership practice that shapes program culture, faculty development, and student outcomes. Drawing on decades of experience as a program director, department chair, and national leader, Dr. Mund explains what's usually true long before a successful COA site visit ever begins.  Here's some of what you'll hear in this episode:

Send Dr. Li a text here. Please leave your email address if you would like a reply, thanks.In this inspiring episode of the Make Time for Success podcast, host Dr. Christine Li welcomes back Megan Blacksmith, an NLP expert, speaker, and co-founder of Zesty. Together, they dive deep into visualization and neuro linguistic programming (NLP) as powerful tools for breaking old patterns, manifesting dreams, and achieving lasting inner transformation. Megan Blacksmith shares her story of accidental visualization, practical techniques for rewiring your mindset, and guidance on moving through resistance and limiting beliefs. You'll hear real-world examples and actionable strategies to help you create your ideal future—one that's possible, even if it feels out of reach today. Get ready to discover the secrets to manifesting your dreams with clarity, creativity, and confidence!Timestamps:00:00:00 - 00:02:47: Dr. Christine Li introduces the episode and welcomes Megan Blacksmith, who shares her expertise in NLP.00:02:48 - 00:05:35: Megan Blacksmith discusses her entry into NLP, its impact on her coaching, and how subconscious programming affects results.00:05:36 - 00:14:06: Exploration of how emotional events and hidden beliefs hold people back, including analogies like clutter.00:14:06 - 00:18:27: Discussing discomfort as a sign of growth and the challenges of stepping into a new identity.00:24:33 - 00:32:40: Insights into using visualization for goal achievement, with Megan Blacksmith's personal story as an example.00:32:41 - 00:39:00: Detailed visualization tips: make your vision vivid, specific, and emotionally charged.To sign up for the Waitlist for the Simply Productive Program, go to https://maketimeforsuccesspodcast.com/SPFor more information on the Make Time for Success podcast, visit: https://www.maketimeforsuccesspodcast.comGain Access to Dr. Christine Li's Free Resource Library -- 12 downloadable tools and templates to help you bypass the impulse to procrastinate: https://procrastinationcoach.mykajabi.com/freelibraryTo work with Dr. Li on a weekly basis in her coaching and accountability program, register for The Success Lab here: https://www.procrastinationcoach.com/labConnect with Us!Dr. Christine LiWebsite: https://www.procrastinationcoach.comFacebook Group: https://www.facebook.com/groups/procrastinationcoachInstagram: https://www.instagram.com/procrastinationcoach/TikTok: https://www.tiktok.com/@procrastinationcoachThe Success Lab: https://maketimeforsuccesspodcast.com/lab                       Simply Productive: https://maketimeforsuccesspodcast.com/SPMegan BlacksmithWebsite: http://www.becomingzesty.com/Podcast: http://becomingzesty.com/podcastInstagram: https://instagram.com/becomingzestyYouTube: https://www.youtube.com/@becoming_zesty

Pandemic Punch is that “turn the volume down on life” strain that still lets your brain stay online. First hit comes in bright and punchy, fruit and citrus up front, then it slides into a calm, floaty body ease that makes your shoulders drop without instantly stapling you to the couch. The vibe is happy, relaxed, and a little giggly, with a steady “I'm good” headspace.Smell and taste lean fruity-citrus with a skunky tang underneath, like sweet punch with a funky edge. It's the kind of profile that feels fun on the inhale, then settles into that mellow exhale where your body remembers it can unclench.Cannabinoids: THCA 26.291%, Total THC 23.269%, Total cannabinoids 27.137%, CBGA 0.561%, CBC 0.0739%, Δ9-THC 0.2115%, CBD and most minors ND.  Terpenes: β-Caryophyllene 0.689%, D-Limonene 0.352%, Linalool 0.342%, β-Myrcene 0.231%, α-Humulene 0.148%, everything else listed ND in this COA.  Best for: decompressing, pain-tension days, evening wind-down, and laughing at stuff that is not even that funny.Save on Dr Dabber with Code: Cannabisschool10Save on Storz & Bickel with Code : CannabisschoolSave on Santa Cruz Shredder with Code: CSP10Save on Bomb Erigs with Code: CSPScore 100 on your test

The Cheat Sheet is The Murder Sheet's segment breaking down weekly news and updates in some of the murder cases we cover. In this episode, we'll talk about cases from New Hampshire, New Jersey, Colorado, and Mississippi.NBC Boston's coverage of the murder of Judy Lord: https://www.nbcboston.com/news/local/nh-cold-case-unit-to-announce-significant-development-in-decades-old-case/3850076/CBS News's report on developments about Nazeer Hameed's involvement in the murders of Sasikala Narra and her son Anish Narra: https://www.cbsnews.com/philadelphia/news/sasikala-and-anish-narra-maple-shade-nj-cold-case/We also accessed news articles from the Concord Monitor, the Trenton Times, and the South Jersey Times via Newspapers.com.The ruling from the Colorado Court of Appeals on public access issues in the Edward R. Sandoval case about the murder of Dennis Lozoya: https://gazetteedit.wpenginepowered.com/wp-content/uploads/2025/11/22CA0824-Peo-v-Sandoval-10-30-25.pdfThe appeal filed in the case of William Ervin Edwards in the murder case of Robert Davis: https://courts.ms.gov/appellatecourts/docket/sendPDF.php?f=web0001.COA.2025-KA-138.118328.0.pdf&c=99062&a=N&s=2Find discounts for Murder Sheet listeners here: https://murdersheetpodcast.com/discountsCheck out our upcoming book events and get links to buy tickets here: https://murdersheetpodcast.com/eventsOrder our book on Delphi here: https://bookshop.org/p/books/shadow-of-the-bridge-the-delphi-murders-and-the-dark-side-of-the-american-heartland-aine-cain/21866881?ean=9781639369232Or here: https://www.simonandschuster.com/books/Shadow-of-the-Bridge/Aine-Cain/9781639369232Or here: https://www.amazon.com/Shadow-Bridge-Murders-American-Heartland/dp/1639369236Join our Patreon here! https://www.patreon.com/c/murdersheetSupport The Murder Sheet by buying a t-shirt here: https://www.murdersheetshop.com/Check out more inclusive sizing and t-shirt and merchandising options here: https://themurdersheet.dashery.com/Send tips to murdersheet@gmail.com.The Murder Sheet is a production of Mystery Sheet LLC.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

The Joint Readiness Training Center is pleased to present the one-hundredth-and-twenty-second episode to air on ‘The Crucible - The JRTC Experience.' Hosted by MAJ Marc Howle, the Brigade Senior Engineer / Protection Observer-Coach-Trainer, and MAJ David Pfaltzgraff, BDE XO OCT (formerly the BDE S-3 Operations OCT), from Brigade Command & Control (BDE HQ) on behalf of the Commander of Ops Group (COG). Today's guests are senior non-commissioned officers of JRTC: MSG Jared Cawthon, MSG Randell Conway, and SFC Corey Rinn. MSG Cawthon is the BDE Fires Support NCOIC and MSG Conway is the BDE Intelligence NCOIC OCT in Brigade Command & Control (BDE HQ). SFC Rinn is the Explosive Ordinance Disposal Senior OCT for TF-5 (BDE Engineer BN).   This episode focuses on leadership through the deliberate and effective utilization of Noncommissioned Officers at echelon, emphasizing that success in LSCO is fundamentally leader business, not officer business versus NCO business. A central theme is the NCO's role in identifying and mitigating friction before it manifests in execution. Drawing on repeated JRTC observations, the discussion highlights how experienced NCOs sharpen plans through rehearsals, checklists, and anticipation of second- and third-order effects—time, distance, sustainment, displacement, and execution risk—that are often missed in rushed or staff-centric planning. When NCOs are fully integrated into MDMP, mission analysis, COA development, and rehearsals, staffs are more synchronized, plans are more executable, and formations adapt faster once friction is encountered.    The episode also addresses persistent gaps in how formations employ NCOs, particularly on staffs. Too often, senior NCOs are relegated to security or administrative tasks instead of being empowered contributors to planning, targeting, and cross–warfighting function integration. The panel underscores disciplined initiative, delegation of authority, and clear roles and responsibilities as decisive leadership practices that unlock NCO potential. Effective formations deliberately train NCOs to operate confidently in planning environments, leverage their experience to challenge assumptions, and serve as connective tissue between operations, intelligence, fires, sustainment, and protection. The consistent takeaway is clear: units that empower NCOs as planners, synchronizers, and leaders—not just executors—operate with less friction, greater cohesion, and higher combat effectiveness in the hardest fights.    Part of S13 “Hip Pocket Training” series.   For additional information and insights from this episode, please check-out our Instagram page @the_jrtc_crucible_podcast   Be sure to follow us on social media to keep up with the latest warfighting TTPs learned through the crucible that is the Joint Readiness Training Center.   Follow us by going to: https://linktr.ee/jrtc and then selecting your preferred podcast format.   Again, we'd like to thank our guests for participating. Don't forget to like, subscribe, and review us wherever you listen or watch your podcasts — and be sure to stay tuned for more in the near future.   “The Crucible – The JRTC Experience” is a product of the Joint Readiness Training Center.

Friend, we obsess over steps, macros, and workout streaks… but when was the last time you checked in on your emotional fitness? In this episode, Nicole sits down with clinical psychologist, emotional fitness expert, and Coa co-founder Dr. Emily Anhalt to talk about what it actually looks like to “train your brain” — no toxic positivity, no “just meditate more,” and definitely no pretending everything's fine when it's very much not.  Emily breaks down her 7 traits of emotional fitness (think mindfulness, curiosity, boundaries, resilience, empathy, communication, and play) and how to build them like muscles over time — one emotional push-up at a time. We get into why empathy without boundaries will burn you all the way out, how to ask for feedback without spiraling into defensiveness, and why trusting your future self might be the most confidence-building thing you do this year.  If you've ever felt resentful because you said “yes” when every cell in your body wanted to say “no,” if you're tired of carrying everyone else's emotions like luggage, or if anxiety and uncertainty have been driving the bus lately, this one's for you. Emotional fitness won't stop life from throwing heavy shit your way — but it will make you strong enough to carry it, move it, and eventually put it down. We explore: What emotional fitness actually means (and how it's different from “fixing yourself”) The 7 traits of emotional fitness — and why you don't have to master all of them at once How to spot the cost of avoiding discomfort (hello, resentment and burnout)The “emotional push-up” exercise you can start doing today How to hold empathy and boundaries so caring for others doesn't drain you dry The best advice Emily ever got for dealing with anxiety and uncertainty Why trusting your future self is a deeply confident way to live Because when you trust your future self, you stop living in panic about what might happen and start living with confidence in who you're becoming — and that shifts everything.  Thank you to our sponsors! Get 20% off your first order at curehydration.com/WOMANSWORK with code WOMANSWORK — and if you get a post-purchase survey, mention you heard about Cure here to help support the show!  Sex is a skill. Beducated is where you learn it. Visit https://beducate.me/pd2550-womanswork and use code womanswork for 50% off the annual pass. Connect with Emily: Website: https://www.dremilyanhalt.com/ Book: https://a.co/d/couFOLN IG: https://www.instagram.com/dremilyanhalt/ X: https://x.com/dremilyanhalt LI: https://www.linkedin.com/in/dremilyanhalt/ Related Podcast Episodes Your Brain Is a Filthy Liar with Bizzie Gold | 361 How To Play: Shift Your Thinking, Inspire Connection & Spark Creativity with Cas Holman | 355 144 / Jay & Nicole Kalil on Partnership, With Guest Host Lynn Casaletto Share the Love: If you found this episode insightful, please share it with a friend, tag us on social media, and leave a review on your favorite podcast platform!

This week, I talk with Dr. Emily Anhalt—a clinical psychologist, founder, and writer who's spent the past 15 years exploring what it really means to be emotionally healthy. You might know her from her TED Talk or her work at Coa, but in this conversation, we go deeper. We talk about growing up in Silicon Valley, the pressure of being a high-achieving kid, and why so many successful people still carry unresolved grief. Emily shares how ADHD shaped her early life, what led her to leave pre-med for psychology, and how emotional patterns from childhood often resurface in our work and relationships. We also dive into what actually makes therapy effective and why hitting your goals doesn't always bring peace. If you've ever built something meaningful but still felt unsettled, or questioned what's really driving your ambition, I think this episode will speak to you. Let's get to it. In this episode: (00:00) - Intro (02:52) - How a beanbag chair and snacks helped Emily unlock her best work (08:01) - Growing up inside the Silicon Valley success machine (09:45) - Why high performers need a different kind of therapy  (11:53) - The story of Emily's parents and how they ended up in the Valley (13:54) - Reframing ADHD as a strength, not a stigma (16:33) - The early experiences that shaped Emily's emotional lens (23:40) - How Emily chose psychology—and what kept her going (28:40) - The moment therapy stopped being about symptoms (33:06) - Why grief is a necessary companion to growth (38:21) - The origin story of a company built around emotional fitness (42:30) - What changes when you go from therapist to founder (45:27) - The qualities of high-integrity therapy (51:26) - How Emily knew it was time to write a book (58:20) - What really keeps entrepreneurs stuck—and how to get unstuck (01:02:09) - What it feels like when success leaves you empty (01:05:32) - How to rebuild when your goals stop making sense (01:07:44) - Why achieving meaning isn't the same as feeling it (01:11:06) - Why therapy often gets harder before it gets better (01:12:47) - Abandoning hard feelings before healing happens (01:13:40) - The isolation of success—and how to find support (01:21:17) - How overachievers get trapped in burnout (01:29:26) - Healthy ways to process anger (01:33:46) - What makes Emily world-class? (01:34:09) - Emily's most beautiful future (01:34:49) - Who Emily is becoming Get full show notes and links at https://GoodWorkShow.com.Watch the episode on YouTube: https://www.youtube.com/@barrettabrooks.

Welcome to Go Gaddis Real Estate Radio! I'm Cleve Gaddis, here to make real estate clear, simple, and worry-free so you can buy and sell with complete confidence and without the stress or second-guessing that often comes with life's biggest investments. Today, we continue our conversation with Michael Crew, CEO of Homeowner Management Services, Inc., to talk about the practical side of community governance. Whether you're in an HOA or a COA, the legal structure of your community affects what you own, what you're responsible for, and how your property is protected. Using insights from the attached script, “Making It Legal — and Protecting Your Property,” we break down: What everyday responsibilities change depending on whether you're in an HOA or COA How maintenance, repairs, reserves, and assessments are handled differently What homeowners must legally maintain vs. what the association maintains How insurance coverage changes — and the expensive surprises homeowners can avoid Why understanding your governing documents protects your property value What rights homeowners gain or lose depending on the structure of their community Most importantly, we'll explain why legal clarity matters — and how knowing the structure of your community can save you time, money, and frustration. Plus, I'll share details about our Upside Program, designed to give sellers all the options they need to make smart, informed decisions. If you have a question, want to challenge something you hear, or want us to feature your neighborhood, visit GoGaddisRadio.com to connect or subscribe.

Welcome to Go Gaddis Real Estate Radio! I'm Cleve Gaddis—here to make real estate clear, simple, and worry-free. Today we're tackling a question that confuses homeowners, buyers, and even some agents: Can a COA become an HOA? And what's the real difference between the two? Joining me is Michael Crew, CEO of Homeowner Management Services, Inc., one of Atlanta's most trusted experts in community association management. We'll break down: What separates a Condominium Owners Association (COA) from a Homeowners Association (HOA) Why the appearance of a community can be misleading—townhomes can be condos, and detached homes can be part of a COA Whether a COA can ever “convert” into an HOA (and why it's far more complicated than most people think) How a community's legal documents—not the architecture—determine its ownership structure What buyers and sellers must review before making decisions, including the Declaration of Condominium and the property's legal description How an experienced agent can help you locate, interpret, and understand these documents before you sign anything We'll also share insights from “The Neighborhood That Wanted a Do-Over,” a real-world example of what happens when a community discovers they're operating under the wrong governance structure—and what it takes to fix it. Plus, I'll tell you more about our Upside program, built to give buyers and sellers all the tools and options they need to move forward with confidence. Got a question, comment, or challenge? Visit GoGaddisRadio.com to connect, push back, or subscribe so you never miss an episode.

Key Topics Covered:What gridlines actually doEarth's energetic nervous systemGridlines as frequency transmitters, memory holders, and field mirrorsWhy you're drawn to certain placesMemory completionSignal amplificationTrauma pattern magnetizationArchetypal field recognitionWhy astrocartographic lines may not “feel good”Activation ≠ resonanceField incoherence, premature arrival, or bypass patternsDistortion through unresolved nervous system codingWhat it means to transcend gridlinesFrom memory loop to field stabilityBehavior and perception shifts when the line no longer organizes your fieldThe deeper paradox of place, identity, and safetyBelonging vs becomingSettling vs expandingMovement as control vs contactKey Questions Explored:Where was I when I first felt safe in my body? Is that memory tied to a place—or a presence?What are the somatic cues of safety when there's no cognitive memory?What am I postponing by not allowing myself to belong somewhere?Is my constant movement about expansion—or avoidance of collapse?If I could feel safe in my own field, would the question of “place” still matter?Does astrology and numerology actually affect people?--------Follow @whoistaliyah // @superfreq.coA high vibe podcast ya'll exploring all things Frequencies— How they govern form, shape our realities, and are the key to living from your full potential. It's non-woo convos about super woo shit—Unpacking what I call the “Science of Self” From body and soul literacy to the power of understanding vibration, higher consciousness, quantum physics and spiritual psych, let this podcast become a resource for you on your journey to self-mastery. If you're curious and ready to free your mind, unlock the body and, become limitless then you're in the right place. I'm your host Talie and this is SuperFreq—awakening for the next gen. Stay Curious, Question Everything

This week on "Off the Cuff," Tim and David do a deep dive into the cost of attendance (COA). David begins the conversation by discussing the purpose of COA, and its different categories. From there, Tim and David discuss multiple aspects of COA, including how institutions build their COA and additional fees – such as health insurance and student loan fees. The team also details resources and provides examples to help members better understand COA, including AskRegs answers and an upcoming NASFAA U course dedicated to the topic. 

In this episode of Status Check with Spivey, Spivey consultant and former admissions dean Nikki Laubenstein discusses the financial aid and student loan considerations that prospective law students should be thinking about post-"Big Beautiful Bill," joined by Sydney Montgomery, who is the Executive Director & Founder of Barrier Breakers, and Kristin Shea, who has led the law school financial aid office at Syracuse University for almost a decade as a part of a 20-year career in legal education.Nikki, Sydney, and Kristen talk about the changes to student loans and student loan caps resulting from the One Big Beautiful Bill Act (9:43), the changes to repayment plans (35:58), who those changes apply to (5:21), the differences between undergraduate financial aid/scholarships and law school financial aid/scholarships (20:52), understanding tuition vs. total cost of attendance and how that relates to scholarship reconsideration and student loan caps (24:17), possible ways schools could help fill the gap especially for students targeting public interest jobs (38:21), advice for those planning to work while in law school (41:00), why prospective law students should start thinking about financial aid earlier on in the admissions process than most do (30:47), and more.Barrier Breakers is a nonprofit that has worked with 7,000+ first-generation and other marginalized students on the college and law school application process. Sydney Montgomery, the daughter of a Jamaican immigrant mother and military parents, was the first person from her high school to go to Princeton University and then later Harvard Law School. She has dedicated her life and career to supporting first-generation students and has a particular passion for financial aid. She is a member of the Forbes Nonprofit Council and has been featured in Inc., Forbes, FastCompany, Medium, CNBC, and others. Kristin Shea is a higher education professional with twenty years of experience, including law school enrollment management, recruitment, and financial aid; alumni, donor, and employer relations; and marketing and communications. The last decade of her career has been dedicated to financial aid, and she is passionate about helping law students make smart, thoughtful financial plans for their education. She holds a bachelor's degree in biology and psychology and an MBA from Le Moyne College.We hope to do a follow-up episode in the spring with more information on how law schools are addressing these changes. We also encourage you to reach out to the financial aid offices of schools you're considering once admitted to learn about any programs they may offer and any assistance they can provide. As Kristin says in this episode, "The map may have some alternative directions, but you can still reach your destination, and there are many people who want to help." We have also linked a number of financial aid resources below.Federal Student Aid:FAFSA® Application | Federal Student Aid – 2026-27 FAFSA available noOne Big Beautiful Bill Act Updates | Federal Student AidRepaying Student Loans 101 | Federal Student AidWhat does cost of attendance (COA) mean? | Federal Student Aid AccessLex Institute Resources:Student Loan Calculator | AccessLexStudent Aid Policy and Action Center | AccessLexPaying for Law School | AccessLexGuide to Private Student Loans | AccessLexScholarship Databank | AccessLex – includes more than 800 law scholarship and writing competitions (totaling more than $3M).Free Credit Report:Annual Credit Report.com - Home PageEqual Justice Works – LRAP FAQImportant Questions to Ask About Any LRAP  - Equal Justice Works--You can listen and subscribe to Status Check with Spivey on ⁠⁠Apple Podcasts⁠⁠, ⁠⁠Spotify⁠⁠, and ⁠⁠YouTube⁠⁠. You can read a full transcript (with timestamps) here.

In this episode, you'll learn:Why the “new patient volume rollercoaster” happens—and how to stop itWhat makes the COA role a must-have in every growth-focused clinicThe biggest hiring and management mistakes (and how to avoid them)The exact KPIs and accountability systems that drive consistent new patient flowProven call metrics from top COAs (8–12 hours/week, 1,200+ calls/month!)How to build the culture, systems, and communication loops that keep your outreach thrivingNext Steps:

visit: https://www.benbikman.comvisit: https://insuliniq.com In this Metabolic Classroom lecture, Dr. Bikman explores the deep biochemical relationship between stress and ketone production, uncovering how the body interprets stress signals as cues to mobilize fat and create ketones.He explains how stress hormones—like epinephrine, cortisol, glucagon, and growth hormone—aren't just emergency signals but actually metabolic adaptation hormones that help the body shift into fat-burning mode. Through the sympathetic nervous system and hormone cascades, the body responds to stress by increasing lipolysis and triggering ketogenesis, even during fasting, exercise, or low-carb eating.Ben walks through how ketogenesis begins at the level of fat cells and liver mitochondria, and how key molecules like acetyl-CoA and oxaloacetate determine whether the body makes glucose or ketones.Importantly, he clarifies that while stress can trigger positive metabolic shifts, chronic stress without relief can lead to harmful insulin resistance. The takeaway: understanding the difference between acute and chronic stress is key to using this response to your metabolic advantage. Hosted on Acast. See acast.com/privacy for more information.

We are LIVE from Hyatt Place in Cape Canaveral before our Johnny's House cruise sets sail! Some of the cruisers are going on their first cruise and we hear from people who have traveled from Arizona to be with us! We had the BEST dinner at Coa last night ... when did you have the best meal! See omnystudio.com/listener for privacy information.

Story at-a-glance Research shows vitamin B12 rapidly replenishes adenosine triphosphate (ATP) levels in pancreatic cells, preventing destructive enzyme activation that causes acute pancreatitis inflammation People with naturally higher vitamin B12 levels show significantly lower risk of developing acute pancreatitis, independent of lifestyle factors Vitamin B12 enhances energy metabolism by converting methylmalonyl-CoA to succinyl-CoA, stabilizing cell membranes and containing digestive enzymes properly Early vitamin B12 administration provides greatest protection, with 1,000-2,000 micrograms daily recommended for supplementation or monthly injections for severe deficiency Combine vitamin B12-rich foods like grass fed liver alongside minimal vegetable oil intake and regular exercise to support overall pancreatic health